Endocrinology and Metabolism

Original Article

Adrenal gland
Liquid Chromatography-Tandem Mass Spectrometry Outperforms Radioimmunoassay in Guiding Surgical Decisions Based on Adrenal Venous Sampling in Primary Aldosteronism: Bo-Ching Lee, Chien-Wei Huang, Chin-Chen Chang, Guan-Yuan Chen, Jia-Zheng Huang, Pin-Chen Chen, Te-I Weng, Kao-Lang Liu, Vin-Cent Wu, Yen-Hung Lin, on Behalf of the TAIPAI Study Group; Endocrinol Metab. 2025;40(6):1002-1011. Published online July 1, 2025; DOI: https://doi.org/10.3803/EnM.2024.2237

1,654 View
53 Download

Abstract PDF Supplementary Material PubReader ePub: Background
Adrenal venous sampling (AVS) is essential for diagnosing unilateral aldosterone oversecretion in primary aldosteronism (PA). Traditionally, AVS relies on radioimmunoassay (RIA) to measure plasma aldosterone concentration (PAC), although RIA has limited specificity and considerable variability. This study evaluated the role of liquid chromatography-tandem mass spectrometry (LC-MS/MS) in AVS and its impact on clinical outcomes.
Methods
Among 230 patients with PA (May 2020 to April 2023) who underwent AVS, successful sampling was achieved in 182 patients (79.1%) under unstimulated conditions and 206 patients (89.6%) under stimulated conditions. PAC levels from peripheral and adrenal veins measured by LC-MS/MS were compared with RIA results. Patient outcomes were categorized according to the Primary Aldosteronism Surgical Outcomes criteria.
Results
LC-MS/MS showed significant correlations with PAC levels measured by RIA in AVS (r=0.40 [unstimulated] and r=0.56 [stimulated]; both P<0.001). However, lateralization concordance between RIA and LC-MS/MS was moderate, at only 57.7% (unstimulated) and 64.6% (stimulated). LC-MS/MS identified more unilateral disease than RIA under both unstimulated (61.5% vs. 37.4%, P<0.001) and stimulated conditions (36.4% vs. 9.7%, P<0.001). Patients achieving complete clinical success after adrenalectomy were more accurately identified by LC-MS/MS than RIA under stimulated (55.6% vs. 22.2%, P=0.035), but not in unstimulated conditions.
Conclusion
LC-MS/MS outperformed RIA in identifying unilateral disease, resulting in higher rates of complete clinical success in adrenalectomy patients when surgical decisions were based on LC-MS/MS lateralization results.

Review Article

Adrenal gland
The Fascinating Interplay between Growth Hormone, Insulin-Like Growth Factor-1, and Insulin: Eline C. Nijenhuis-Noort, Kirsten A. Berk, Sebastian J. C. M. M. Neggers, Aart J. van der Lely; Endocrinol Metab. 2024;39(1):83-89. Published online January 9, 2024; DOI: https://doi.org/10.3803/EnM.2024.101

129,360 View
1,341 Download
33 Web of Science
38 Crossref

Abstract PDF PubReader ePub

This review intends to provide the reader with a practical overview of several (patho)physiological conditions in which knowledge of the interplay between growth hormone (GH), insulin-like growth factor-1 (IGF-1), and insulin is important. This might help treating physicians in making the right decisions on how to intervene and improve metabolism for the benefit of patients, and to understand why and how metabolism responds in their specific cases. We will specifically address the interplay between GH, IGF-1, and insulin in type 1 and 2 diabetes mellitus, liver cirrhosis, and acromegaly as examples in which this knowledge is truly necessary.

Citations

Citations to this article as recorded by

Zhi-Shen Pill ameliorates impaired glucose tolerance by targeting pancreatic β-cell and adipocyte pathways
Yinshan Huang, Xuan Ren, Xiudao Song, Kaiwen Xu, Lijuan Jin, Hui Zhu, Wei Chen, Wei Mu, Chunbo Jiang, Guoqiang Liang
Journal of Ethnopharmacology.2026; 357: 120931. CrossRef
Dairy intake and risk of type 2 diabetes and metabolic syndrome: A narrative review
Karani Santhanakrishnan Vimaleswaran, Viswanathan Mohan
Nutrition.2026; 144: 113064. CrossRef
Maternal diet shapes milk bile acids to regulate neonatal growth through TGR5
Lufuno Phophi, Haley M. Wilt, Zhengzheng Hu, Rishi Gadikota, Mallory Cadiz, Mikayla S. Manzi, Freddie D. Ortiz Martinez, Sarayu Vanga, Elizabeth G. Chapman, Scott A. Tibbetts, Stephanie M. Karst
Cell Reports.2026; 45(1): 116744. CrossRef
Dietary Defective Jujube as a Corn Substitute: Impacts on Growth Performance, Meat Traits, and Alternaria Toxin Exposure in Lambs
Letian Zhang, Haoyang Hui, Muhammad Faheem, Yanfeng Xue, Ning Chen, Xiaoling Zhou
Animals.2026; 16(2): 255. CrossRef
Insulin Receptor Family Autoantibodies in Patients with Type B Insulin Resistance
Jennifer E Lee, Thilo S Chillon, Waldemar B Minich, Brent S Abel, Marissa Lightbourne, Lutz Schomburg, Rebecca J Brown
The Journal of Clinical Endocrinology & Metabolism.2026;[Epub] CrossRef
The relationship between IGF-1 and cardiovascular diseases and the potential mediating role of TyG-related index: evidence from a cohort study
Haipeng Chen, Ning Huang, Yang Huang, Jin Chen, Xu Luo
BMC Cardiovascular Disorders.2026;[Epub] CrossRef
Insulin-Like Growth Factor Signaling in Alzheimer’s Disease: Pathophysiology and Therapeutic Strategies
Jie Miao, Yanli Zhang, Chen Su, Qiandan Zheng, Junhong Guo
Molecular Neurobiology.2025; 62(3): 3195. CrossRef
GHRH in diabetes and metabolism
Charlotte Steenblock, Stefan R. Bornstein
Reviews in Endocrine and Metabolic Disorders.2025; 26(3): 413. CrossRef
Signaling pathways and targeted therapies in Ewing sarcoma
Ke Jia, Li Cao, Yihan Yu, Doudou Jing, Wei Wu, Brian Andrew Van Tine, Zengwu Shao
Pharmacology & Therapeutics.2025; 266: 108765. CrossRef
Expanding the Clinical and Mutational Spectrum of Biallelic POC1A Variants: Characterization of Four Patients and a Comprehensive Review of POC1A‐Related Phenotypes
Umut Altunoglu, Gozde Tutku Turgut, Esin Karakılıç Özturan, Tuğba Kalaycı, Mert Kaya, Güven Toksoy, Firdevs Baş, Hülya Kayserili, Feyza Darendeliler
Clinical Genetics.2025; 107(4): 390. CrossRef
Bridging Pubertal Changes and Endotype Based Therapy in Type 1 Diabetes
M. A. Roma‐Wilson, R. Buzzetti, S. Zampetti
Diabetes/Metabolism Research and Reviews.2025;[Epub] CrossRef
Training with electrical muscle stimulation: a novel method to improve Body Mass Index, lipid profile, growth hormone, and cortisol in overweight subjects
Elnaz RIYAHI, Jalil REISI, Sayyed M. MARANDI, Milad ABDOLLAHI
The Journal of Sports Medicine and Physical Fitness.2025;[Epub] CrossRef
Bilateral ovarian juvenile granulosa cell tumor in a neonate with Donohue syndrome: a case report and review of literature
Amany Reda Elbahbity, Amr Abdelhamid AbouZeid, Mohammad Hassan Mohamed, Mohammad Hassan Elibiary, Soha M. khafagy, Amira Mostafa Rashad, Shaimaa Mahmoud Abdelraouf, Sohair Abdelbaset Zayed, Manal Fawzy Gadalla, Shaimaa Abdelsattar Mohammad
Egyptian Pediatric Association Gazette.2025;[Epub] CrossRef
Association of IGF-1 and IGFBP-3 with metabolic abnormalities among children and adolescents
Zhenghao Zhao, Yuanyuan Ma, Xinyi Zhang, Xiaoxiao Liu, Yang Li, Zhongze Fang, Rongxiu Zheng, Jing Li
Frontiers in Endocrinology.2025;[Epub] CrossRef
Early Cardiovascular and Metabolic Benefits of rhGH Therapy in Adult Patients with Severe Growth Hormone Deficiency: Impact on Oxidative Stress Parameters
Maria Kościuszko, Angelika Buczyńska, Justyna Hryniewicka, Dorota Jankowska, Agnieszka Adamska, Katarzyna Siewko, Małgorzata Jacewicz-Święcka, Marcin Zaniuk, Adam Jacek Krętowski, Anna Popławska-Kita
International Journal of Molecular Sciences.2025; 26(12): 5434. CrossRef
Effects of warm-season feeding on yak growth, antioxidant capacity, immune function, and fecal microbiota
Yining Xie, Yangji Cidan, Zhuoma Cisang, Deji Gusang, Quzha Danzeng, Wangdui Basang, Yanbin Zhu, Jinshui Lin, Lizhuang Hao, Tariq Shah
Microbiology Spectrum.2025;[Epub] CrossRef
Post-Exercise Whey Protein Supplementation: Effects on IGF-1, Strength, and Body Composition in Pre-Menopausal Women, a Randomised Controlled Trial
Marc Murray, Lara Vlietstra, Alyssa M. D. Best, Stacy T. Sims, James A. Loehr, Nancy J. Rehrer
Nutrients.2025; 17(12): 2033. CrossRef
Diagnostic accuracy of triglyceride to glucose index and triglyceride/high-density lipoprotein index for insulin resistance among children and adolescents: A systematic review
Miguel Cabanillas-Lazo, Carlos Quispe-Vicuña, Milagros Pascual-Guevara, Claudia Cruzalegui-Bazán, Arturo Duran-Pecho, José Paz-Ibarra, Victor Velásquez-Rimachi, Qian Wu
PLOS One.2025; 20(6): e0326179. CrossRef
Diabetes and Bone Health: A Comprehensive Review of Impacts and Mechanisms
Prabhat Upadhyay, Sudhir Kumar
Diabetes/Metabolism Research and Reviews.2025;[Epub] CrossRef
Targeting cardiometabolic risk in type 1 diabetes through incretin physiology
Ruth Frampton, Samantha Hocking, Jennifer R. Snaith, Jerry R. Greenfield
Trends in Endocrinology & Metabolism.2025;[Epub] CrossRef
High Blood Lead Levels as A Risk Factor of Stunting: A Study of Children in Agricultural Areas
Alfan Afandi, Suhartono Suhartono, Budiyono Budiyono, Ani Margawati, Apoina Kartini
JURNAL KESEHATAN LINGKUNGAN .2025; 17(1): 45. CrossRef
Viral Infections in Type 2 Diabetes: A Dangerous Liaison
Azizul Haque, Anudeep B. Pant
Viruses.2025; 17(9): 1150. CrossRef
Intranasal nanoparticle therapy for arsenic-induced neurotoxicity: Restoring IGF-1 signaling and advancing translational neuroprotection
Nourhan Elsayed, Jhi Biau Foo
Neuroscience.2025; 585: 107. CrossRef
Serum IGF-1 May be less reliable when assessing the GH-IGF-1 axis in the elderly
Angelo Milioto, Gudmundur Johannsson, Daniela Esposito
Pituitary.2025;[Epub] CrossRef
Sex Hormones and Metabolic Dysfunction-Associated Steatotic Liver Disease
Ralf Weiskirchen, Amedeo Lonardo
International Journal of Molecular Sciences.2025; 26(19): 9594. CrossRef
Critical regulatory roles of non-coding RNAs in driving cancer sensitivity to Carmustine: a systematic review
Seyed Mostafa Rahimi, Abouzar Bagheri
Naunyn-Schmiedeberg's Archives of Pharmacology.2025;[Epub] CrossRef
Regenerative therapeutic effects of conditioned medium from human umbilical cord‑derived mesenchymal stem cells as an adjuvant to insulin therapy in a rat model of type 2 diabetes
Siufui Hendrawan, Jennifer Lheman, Olivia Marcelina, Lydia Tantoso, Hans Baer, Shirly Gunawan
World Academy of Sciences Journal.2025; 7(6): 1. CrossRef
Prevalence of Liver Steatosis and Fibrosis Assessed by Transient Elastography in a High Cardiovascular-Risk Outpatient Cohort Including T1DM and T2DM Patients
Alina N. Saidi, Willy B. Theel, Diederick E. Grobbee, Aart-Jan van der Lely, Femme Dirksmeier-Harinck, Marco Alings, Ellen van der Zwan-van Beek, Simone P. Rauh, Moniba Rasheed, Manuel Castro Cabezas
Diabetology.2025; 6(11): 129. CrossRef
Interconnected Mechanistic Pathways, Molecular Biomarkers, and Therapeutic Approach of Oral Cancer in Patients with Diabetes Mellitus
Viviana Elian, Violeta Popovici, Mihnea Ioan Nicolescu, Alexandra Maria Nicolescu, Sorina Maria Aurelian, Emma Adriana Ozon
Current Issues in Molecular Biology.2025; 47(11): 929. CrossRef
Adverse events with usage of human growth hormone: a review
Ludwik K. Branski, Sarita Thanedar, Nafis Deen, Kevin W. Cho, Gongkai Liu, Gabriel Hundeshagen, David N. Herndon, Linda E. Sousse
Discover Medicine.2025;[Epub] CrossRef
Unlocking Gut-Driven Metabolic Repair: The Role of Glucomannan Porang (Amorphophallus muelleri Blume) in Insulin Resistance and Short-Chain Fatty Acid Modulation in a Type 2 Diabetes Mellitus Rat Model
Azizah H. Safitri, Rahmata A. Sayyida, Eni Widayati, Nurina Tyagita
Tropical Journal of Natural Product Research.2025;[Epub] CrossRef
Effects of Short-Term (20-Day) Alternate-Day Modified Fasting and Time-Restricted Feeding on Fasting Glucose and IGF-1 in Obese Young Women
Dian Aristia Rachmayanti, Purwo Sri Rejeki, Raden Argarini, Hermina Novida, Sri Soenarti, Shariff Halim, Chy’as Diuranil Astrid Permataputri, Sheeny Priska Purnomo
Diseases.2025; 13(12): 390. CrossRef
Human growth hormone‐induced mitotic maladaptation in podocytes and implications in diabetic kidney disease
Bharath Banoth, Sumathi Raviraj, Anil Kumar Pasupulati
Journal of Neuroendocrinology.2025;[Epub] CrossRef
Human Cancers Derived from Either Genetic or Lifestyle Factors Are Initiated by Impaired Estrogen Signaling
Zsuzsanna Suba
Cancers.2025; 18(1): 78. CrossRef
IGF-1 and IGF-2 as Molecules Linked to Causes and Consequences of Obesity from Fetal Life to Adulthood: A Systematic Review
Justyna Szydlowska-Gladysz, Adrianna Edyta Gorecka, Julia Stepien, Izabela Rysz, Iwona Ben-Skowronek
International Journal of Molecular Sciences.2024; 25(7): 3966. CrossRef
Insulin resistance reduction, intermittent fasting, and human growth hormone: secondary analysis of a randomized trial
Benjamin D. Horne, Jeffrey L. Anderson, Heidi T. May, Tami L. Bair, Viet T. Le, Leslie Iverson, Kirk U. Knowlton, Joseph B. Muhlestein
npj Metabolic Health and Disease.2024;[Epub] CrossRef
Growth hormone/insulin-like growth factor I axis in health and disease states: an update on the role of intra-portal insulin
Kevin C. J. Yuen, Rikke Hjortebjerg, Ashok Ainkaran Ganeshalingam, David R. Clemmons, Jan Frystyk
Frontiers in Endocrinology.2024;[Epub] CrossRef
Comprehensive Management of Diabetes Mellitus in the Elderly: A Review
Bharat Kumar, Ravi Kant, Gopal Krishana Bohra
Journal of Cardio-diabetes and Metabolic Disorders.2023; 3(2): 21. CrossRef

Original Articles

Miscellaneous
AM1638, a GPR40-Full Agonist, Inhibited Palmitate- Induced ROS Production and Endoplasmic Reticulum Stress, Enhancing HUVEC Viability in an NRF2-Dependent Manner: Hwan-Jin Hwang, Joo Won Kim, SukHwan Yun, Min Jeong Park, Eyun Song, Sooyeon Jang, Ahreum Jang, Kyung Mook Choi, Sei Hyun Baik, Hye Jin Yoo; Endocrinol Metab. 2023;38(6):760-769. Published online November 2, 2023; DOI: https://doi.org/10.3803/EnM.2023.1774

5,620 View
125 Download
7 Web of Science
8 Crossref

Abstract PDF PubReader ePub

Background
G protein-coupled receptor 40 (GPR40) is a key molecule in diabetes and fatty liver, but its role in endothelial dysfunction remains unclear. Our objective in this study was to determine whether GPR40 agonists protect endothelial cells against palmitatemediated oxidative stress.
Methods
Human umbilical vein endothelial cells (HUVECs) were used to investigate effects of various GPR40 agonists on vascular endothelium.
Results
In HUVECs, AM1638, a GPR40-full agonist, enhanced nuclear factor erythroid 2–related factor 2 (NRF2) translocation to the nucleus and heme oxygenase-1 (HO-1) expression, which blocked palmitate-induced superoxide production. Those antioxidant effects were not detected after treatment with LY2922470 or TAK875, GPR40-partial agonists, suggesting that GPR40 regulates reactive oxygen species (ROS) removal in a ligand-dependent manner. We also found that palmitate-induced CCAAT/enhancer‐binding protein homologous protein expression; X-box binding protein-1 splicing, nuclear condensation, and fragmentation; and caspase-3 cleavage were all blocked in an NRF2-dependent manner after AM1638 treatment. Both LY2922470 and TAK875 also improved cell viability independent of the NRF2/ROS pathway by reducing palmitate-mediated endoplasmic reticulum stress and nuclear damage. GPR40 agonists thus have beneficial effects against palmitate in HUVECs. In particular, AM1638 reduced palmitate-induced superoxide production and cytotoxicity in an NRF2/HO-1 dependent manner.
Conclusion
GPR40 could be developed as a good therapeutic target to prevent or treat cardiovascular diseases such as atherosclerosis.

Citations

Citations to this article as recorded by

From oxidative stress to metabolic dysfunction: The role of TRPM2
Ying-Shuang Li, Hua-Cheng Ren, Hui Li, Man Xing, Jian-Hua Cao
International Journal of Biological Macromolecules.2025; 284: 138081. CrossRef
Discovery of potent free fatty acid receptor 1 full agonists with a novel scaffold bearing conjugated double bond linker
Ziwei Yang, Jun Sun, Tifei Xu, Yu Wang, Jiahui Fang, Kai Wang, Shimeng Guo, Xin Xie, Jianhua Shen
Bioorganic & Medicinal Chemistry.2025; 123: 118158. CrossRef
GPR40-full agonist AM1638 alleviates palmitate-induced oxidative damage in H9c2 cells via an AMPK-dependent pathway
SukHwan Yun, Joo Won Kim, Min Jeong Park, Eyun Song, Soo Yeon Jang, Ahreum Jang, Kyung Mook Choi, Sei Hyun Baik, Hwan-Jin Hwang, Hye Jin Yoo
BMB Reports.2025; 58(3): 133. CrossRef
HD6277 Suppresses Muscle Atrophy by Promoting Myogenic Factors and Inhibiting Proteolysis in Aged Mice
Joo Won Kim, SukHwan Yun, Min Jeong Park, Eyun Song, Sooyeon Jang, Ahreum Jang, Kyung Mook Choi, Sei Hyun Baik, Hwan‐Jin Hwang, Hye Jin Yoo
Journal of Cachexia, Sarcopenia and Muscle.2025;[Epub] CrossRef
Sarcopenic obesity: prospects of mitochondrial transplantation to combat metabolic deterioration in aging
Md Ariful Islam, Wenyi Gu, Yijie Song, Yu Xu, Hongxi Xu
Acta Materia Medica.2025;[Epub] CrossRef
Molecular mechanisms of aberrant fatty acids metabolism in driving cardiovascular diseases: key regulatory targets and dietary interventions
Rui Yang, Jiao Pang, Xue Zhong, Shuyang Pang, Xuefeng Hu, Chenfei Wei, Weiqi Yan, Xueting Chen, Rui Zhao, Baojun Xu, Zhipeng Cao
Food & Function.2025; 16(15): 5961. CrossRef
Hypoglycemic and Analgesic Effects of Benzyloxyphenylpropanoic Derivatives of Isobornylamine as FFAR‐1 Agonists
Mariya A. Elkina, Mikhail V. Khvostov, Sergey O. Kuranov, Olga A. Luzina, Natalia A. Zhukova, Yulia V. Meshkova, Tatiana G. Tolstikova, Nariman F. Salakhutdinov
Archiv der Pharmazie.2025;[Epub] CrossRef
Free Fatty Acids and Free Fatty Acid Receptors: Role in Regulating Arterial Function
Fengzhi Yu, Boyi Zong, Lili Ji, Peng Sun, Dandan Jia, Ru Wang
International Journal of Molecular Sciences.2024; 25(14): 7853. CrossRef

Diabetes, obesity and metabolism
Inhibition of Fatty Acid β-Oxidation by Fatty Acid Binding Protein 4 Induces Ferroptosis in HK2 Cells Under High Glucose Conditions: Jiasi Chen, Keping Wu, Yan Lei, Mingcheng Huang, Lokyu Cheng, Hui Guan, Jiawen Lin, Ming Zhong, Xiaohua Wang, Zhihua Zheng; Endocrinol Metab. 2023;38(2):226-244. Published online April 27, 2023; DOI: https://doi.org/10.3803/EnM.2022.1604

11,808 View
274 Download
24 Web of Science
25 Crossref

Abstract PDF PubReader ePub

Background
Ferroptosis, which is caused by an iron-dependent accumulation of lipid hydroperoxides, is a type of cell death linked to diabetic kidney disease (DKD). Previous research has shown that fatty acid binding protein 4 (FABP4) is involved in the regulation of ferroptosis in diabetic retinopathy. The present study was constructed to explore the role of FABP4 in the regulation of ferroptosis in DKD.
Methods
We first detected the expression of FABP4 and proteins related to ferroptosis in renal biopsies of patients with DKD. Then, we used a FABP4 inhibitor and small interfering RNA to investigate the role of FABP4 in ferroptosis induced by high glucose in human renal proximal tubular epithelial (HG-HK2) cells.
Results
In kidney biopsies of DKD patients, the expression of FABP4 was elevated, whereas carnitine palmitoyltransferase-1A (CP-T1A), glutathione peroxidase 4, ferritin heavy chain, and ferritin light chain showed reduced expression. In HG-HK2 cells, the induction of ferroptosis was accompanied by an increase in FABP4. Inhibition of FABP4 in HG-HK2 cells changed the redox state, sup-pressing the production of reactive oxygen species, ferrous iron (Fe²⁺), and malondialdehyde, increasing superoxide dismutase, and reversing ferroptosis-associated mitochondrial damage. The inhibition of FABP4 also increased the expression of CPT1A, reversed lipid deposition, and restored impaired fatty acid β-oxidation. In addition, the inhibition of CPT1A could induce ferroptosis in HK2 cells.
Conclusion
Our results suggest that FABP4 mediates ferroptosis in HG-HK2 cells by inhibiting fatty acid β-oxidation.

Citations

Citations to this article as recorded by

Enhanced cell survival in prepubertal testicular tissue cryopreserved with membrane lipids and antioxidants rich cryopreservation medium
Reyon Dcunha, Anjana Aravind, Smitha Bhaskar, Sadhana Mutalik, Srinivas Mutalik, Sneha Guruprasad Kalthur, Anujith Kumar, Padmaraj Hegde, Satish Kumar Adiga, Yulian Zhao, Nagarajan Kannan, Thottethodi Subrahmanya Keshava Prasad, Guruprasad Kalthur
Cell and Tissue Research.2025; 399(1): 97. CrossRef
Lipid metabolism in ferroptosis: mechanistic insights and therapeutic potential
Daoyun Sun, Longfei Wang, Yufan Wu, Yi Yu, Yufeng Yao, Hongju Yang, Chunlin Hao
Frontiers in Immunology.2025;[Epub] CrossRef
FABP4 inhibition protects renal tubular cells and ameliorates renal inflammation in diabetic kidney disease
Yen‐Wen Wu, Jaw‐Wen Chen, Liang-Yu Lin, Jih-Hsin Huang, Chia‐Chi Chang, Ting‐Ting Chang
Biochemical Pharmacology.2025; 236: 116899. CrossRef
Mitochondrial CCN1 drives ferroptosis via fatty acid β-oxidation
Wanxin Guo, Congcong Zhang, Qianjun Zhou, Tianxiang Chen, Xin Xu, Jianfeng Zhang, Xuewen Yu, Han Wu, Xiao Zhang, Lifang Ma, Kun Qian, Daniel J. Klionsky, Rui Kang, Guido Kroemer, Yongchun Yu, Daolin Tang, Jiayi Wang
Developmental Cell.2025; 60(17): 2294. CrossRef
Phospholipids and peroxisomes in ferroptosis: the therapeutic target of acupuncture regulating vascular cognitive impairment and dementia
Wenyu Zhang, Ruiyu Li, Donglei Lu, Xinliang Wang, Qiuxuan Wang, Xuyang Feng, Sai Qi, Xuezhu Zhang
Frontiers in Aging Neuroscience.2025;[Epub] CrossRef
Qing-Re-Xiao-Zheng-(Yi-Qi) formula attenuates the renal podocyte ferroptosis in diabetic kidney disease through AMPK pathway
Jiale Zhang, Qiaoru Wu, Chenhui Xia, Huijuan Zheng, Weimin Jiang, Yaoxian Wang, Weiwei Sun
Journal of Ethnopharmacology.2025; 351: 120157. CrossRef
Jianpi Huayu Jiedu Decoction prevents the progression of H. pylori and MNU-induced gastric precancerous lesions by inhibiting ferroptosis and remodeling linoleic acid metabolism
Sijia Zhang, Yage Xiao, Zichun Xie, Silin Liu, Jin Li, Peiyao He, Yongheng Lai, Yu Yin, Hongtong Lin, Huafeng Pan, Chongkai Fang
Journal of Ethnopharmacology.2025; 352: 120217. CrossRef
Overexpression of GPX4 in diabetic rat kidney alleviates renal injury induced by ferroptosis
Keping Wu, Enyi Zhu, Jiasi Chen, Qingyan Kuang, Jiawen Lin, Shuping Zhao, Xiaochang Xu, Shuping Li, Yuan Sui, Mingcheng Huang, Yimin Zhang
BioMetals.2025; 38(4): 1281. CrossRef
Cigarette smoke-induced glycerophospholipid DLPC promotes macrophage ferroptosis through the USP7/GPX4 regulatory axis in chronic obstructive pulmonary disease
Weibin Ruan, Zhimin Peng, Mingsi Huang, Hui Zhang, Xiaohua Li, Tingting Ma, Jiehua Deng, Mianluan Pan, Ziqing Mai, Xia Meng, Jianquan Zhang
Chemico-Biological Interactions.2025; 420: 111697. CrossRef
Analysis and verification of potential ferroptosis-related diagnostic markers in the early stage of metabolic dysfunction-associated steatohepatitis
Qianqian Li, Qianqian Zhang, Aigang Ren, Haiyan Zhang, Lixin Liu
Biochemical and Biophysical Research Communications.2025; 779: 152406. CrossRef
Understanding the Mechanisms of Lipid Metabolism Reprogramming and Ferroptosis in Diabetic Kidney Disease Progression
Yi Zhen Han, Xing Yu Zhu, Yang Zhi Yuan Wang, Bo Xuan Du, Yun Qiao Zhou, Xue Qin Zhang, Yao Xian Wang, Hui Juan Zheng, Wei Jing Liu, Jae Young Je
Journal of Food Biochemistry.2025;[Epub] CrossRef
Programmed Cell Death in Diabetic Kidney Disease: Mechanisms and Therapeutic Targeting
Shanshan Tang, Yuting Sun, Wenjie Sun, Xiaomin Kang, Xuefei Zhao, Linlin Jiang, Qing Gao, Xuedong An, Hangyu Ji, Fengmei Lian
Journal of Inflammation Research.2025; Volume 18: 13001. CrossRef
Targeting ferroptosis and mitochondrial abnormalities: a promising therapeutic strategy for diabetes and its complications
Huayuan Liu, Chen Zhang, Jiuwei Li, Wenchao Gu, Hanyang Yu, Jiaying Song, Yuehan Qu, Guowei Jia, Furong Wang
Life Sciences.2025; 382: 124010. CrossRef
CPT1A facilitated ferroptosis by forming feedback loop with Nrf2 via PI3K/AKT pathway in colorectal cancer
Xiao-huan Li, Feng Lv, Si-qi Li, Hao-wei Deng, Li-ping Tang, Ke-zhi Li, Li-ye Xie, Bang-li Hu, Shu-fang Ning
Apoptosis.2025; 30(11-12): 2899. CrossRef
Mixtures of p,p′-DDE, PCB153, BDE47, and PFOS Alter Adipocytic Differentiation of 3T3-L1 Cells
Melanie M. Garcia, John L. Pearce, Morgan A. Jacobellis, William S. Baldwin, Kelly J. Hunt, Lisa J. Bain
Toxics.2025; 13(11): 975. CrossRef
20(S)-protopanaxatriol ameliorates cardiac hypertrophy by activating the AMPK/PGC-1α/PPARγ signaling pathway
Xue Yan, Huajie Zheng, Ju Ye, Donglin Zhang, Rong Lv, Li Yang, Qiong Lai, Lili Ding, Zhengtao Wang
Journal of Ginseng Research.2025; : 100920. CrossRef
Augmenter of liver regeneration knockout aggravates tubular ferroptosis and macrophage activation by regulating carnitine palmitoyltransferase‐1A‐induced lipid metabolism in diabetic nephropathy
Yuanyuan Zhang, Zheng Zhang, Lili Huang, Chunxia Wang, Pengfei Yang, Ling Zhang, Xiaohui Liao
Acta Physiologica.2024;[Epub] CrossRef
Fatty Acid Binding Protein-4 Silencing Inhibits Ferroptosis to Alleviate Lipopolysaccharide-induced Injury of Renal Tubular Epithelial Cells by Blocking Janus Kinase 2/Signal Transducer and Activator of Transcription 3 Signaling
Suo Xu, Jiye Luo, Yanli Wang, Xiaobing Chen
Journal of Physiological Investigation.2024; 67(1): 47. CrossRef
Ferroptosis in Liver Disease: Natural Active Compounds and Therapeutic Implications
Zhili Wu, Yanru Zhu, Wenchao Liu, Balamuralikrishnan Balasubramanian, Xiao Xu, Junhu Yao, Xinjian Lei
Antioxidants.2024; 13(3): 352. CrossRef
Investigating the Role of FABP4 in Diabetes and Obesity and the Influence of Age and Ethnicity: A Comprehensive Analysis of a Cohort from the KEDP-Study
Mohammed A. Abdalla, Jehad Abubaker, Mohamed Abu-Farha, Irina Al-Khairi, Preethi Cherian, Mohammad G. Qaddoumi, Fatema Al-Rashed, Thangavel Alphonse Thanaraj, Ahmed N. Albatineh, Fahd Al-Mulla
International Journal of Molecular Sciences.2024; 25(9): 4578. CrossRef
Mitochondrial metabolic reprogramming in diabetic kidney disease
Xiaoting Fan, Meilin Yang, Yating Lang, Shangwei Lu, Zhijuan Kong, Ying Gao, Ning Shen, Dongdong Zhang, Zhimei Lv
Cell Death & Disease.2024;[Epub] CrossRef
Inhibition of FABP4 Ameliorates IL-13-Induced Inflammatory Response and Barrier Dysfunction in Nasal Mucosal Epithelial Cells through the Regulation of Ferroptosis
Shanshan Qi
Cell Biochemistry and Biophysics.2024; 83(1): 977. CrossRef
Unraveling Ferroptosis: A New Frontier in Combating Renal Fibrosis and CKD Progression
Rui Jin, Yue Dai, Zheng Wang, Qinyang Hu, Cuntai Zhang, Hongyu Gao, Qi Yan
Biology.2024; 14(1): 12. CrossRef
Mechanisms and regulations of ferroptosis
Xu-Dong Zhang, Zhong-Yuan Liu, Mao-Sen Wang, Yu-Xiang Guo, Xiang-Kun Wang, Kai Luo, Shuai Huang, Ren-Feng Li
Frontiers in Immunology.2023;[Epub] CrossRef
Targeting epigenetic and posttranslational modifications regulating ferroptosis for the treatment of diseases
Yumin Wang, Jing Hu, Shuang Wu, Joshua S. Fleishman, Yulin Li, Yinshi Xu, Wailong Zou, Jinhua Wang, Yukuan Feng, Jichao Chen, Hongquan Wang
Signal Transduction and Targeted Therapy.2023;[Epub] CrossRef

Thyroid
Identification of Mutations in the Thyroxine-Binding Globulin (TBG) Gene in Patients with TBG Deficiency in Korea: Jung Heo, Sang-Mi Kim, Hyun Jin Ryu, Hyunju Park, Tae Hyuk Kim, Jae Hoon Chung, Hyung-Doo Park, Sun Wook Kim; Endocrinol Metab. 2022;37(6):870-878. Published online December 7, 2022; DOI: https://doi.org/10.3803/EnM.2022.1591

6,076 View
223 Download
1 Web of Science
1 Crossref

Abstract PDF Supplementary Material PubReader ePub

Background
Thyroxine-binding globulin (TBG) is a major transporter protein for thyroid hormones. The serpin family A member 7 (SERPINA7) gene codes for TBG, and mutations of the SERPINA7 gene result in TBG deficiency. Although more than 40 mutations have been reported in several countries, only a few studies of TBG deficiency and SERPINA7 gene mutation have been performed in Korea. The aim of this study is to review the clinical presentations and laboratory findings of patients with TBG deficiency and to investigate the types of SERPINA7 gene mutation.
Methods
Five unrelated Korean adults with TBG deficiency attending endocrinology clinic underwent SERPINA7 gene sequencing. Four patients harbored a SERPINA7 gene mutation. Serum thyroid hormones, anti-microsomal antibodies, and TBG were measured. Genomic DNA was extracted from whole blood. All exons and intron-exon boundaries of the TBG gene were amplified and sequencing was performed.
Results
Two patients were heterozygous females, and the other two were hemizygous males. One heterozygous female had coexisting hypothyroidism. The other heterozygous female was erroneously prescribed levothyroxine at a local clinic. One hemizygous male harbored a novel mutation, p.Phe269Cysfs*18, which caused TBG partial deficiency. Three patients had the p.Leu372Phefs*23 mutation, which is known as TBG-complete deficiency Japan (TBG-CDJ) and was also presented in previous mutation analyses in Korea.
Conclusion
This study presents four patients diagnosed with TBG deficiency and provides the results of SERPINA7 gene sequencing. One novel mutation, p.Phe269Cysfs*18, causing TBD-partial deficiency and three cases of TBG-CDJ were demonstrated. It is necessary to identify TBG deficiency to prevent improper treatment. Also, sequencing of the SERPINA7 gene would provide valuable information about the TBG variants in Korea.

Citations

Citations to this article as recorded by

Development and basic performance verification of a rapid homogeneous bioassay for agonistic antibodies against the thyroid-stimulating hormone receptor
Motoki Hoshina, Shiomi Ojima, Atsushi Kawasaki, Kosuke Doi, Satoshi Ohta, Asuka Inoue, Hiroshi Murayama
Journal of Immunological Methods.2024; 528: 113655. CrossRef

Miscellaneous
Protective Effect of Delta-Like 1 Homolog Against Muscular Atrophy in a Mouse Model: Ji Young Lee, Minyoung Lee, Dong-Hee Lee, Yong-ho Lee, Byung-Wan Lee, Eun Seok Kang, Bong-Soo Cha; Endocrinol Metab. 2022;37(4):684-697. Published online August 29, 2022; DOI: https://doi.org/10.3803/EnM.2022.1446

8,032 View
194 Download
2 Web of Science
2 Crossref

Abstract PDF Supplementary Material PubReader ePub

Background
Muscle atrophy is caused by an imbalance between muscle growth and wasting. Delta-like 1 homolog (DLK1), a protein that modulates adipogenesis and muscle development, is a crucial regulator of myogenic programming. Thus, we investigated the effect of exogenous DLK1 on muscular atrophy.
Methods
We used muscular atrophy mouse model induced by dexamethasone (Dex). The mice were randomly divided into three groups: (1) control group, (2) Dex-induced muscle atrophy group, and (3) Dex-induced muscle atrophy group treated with DLK1. The effects of DLK1 were also investigated in an in vitro model using C2C12 myotubes.
Results
Dex-induced muscular atrophy in mice was associated with increased expression of muscle atrophy markers and decreased expression of muscle differentiation markers, while DLK1 treatment attenuated these degenerative changes together with reduced expression of the muscle growth inhibitor, myostatin. In addition, electron microscopy revealed that DLK1 treatment improved mitochondrial dynamics in the Dex-induced atrophy model. In the in vitro model of muscle atrophy, normalized expression of muscle differentiation markers by DLK1 treatment was mitigated by myostatin knockdown, implying that DLK1 attenuates muscle atrophy through the myostatin pathway.
Conclusion
DLK1 treatment inhibited muscular atrophy by suppressing myostatin-driven signaling and improving mitochondrial biogenesis. Thus, DLK1 might be a promising candidate to treat sarcopenia, characterized by muscle atrophy and degeneration.

Citations

Citations to this article as recorded by

Advancements in the study of DLK1 in the pathogenesis of diabetes
Min Li, Yanqiu Peng, Yuke Shi, Yunfei Liu, Jian Zhang
Life Sciences.2025; 369: 123535. CrossRef
Molecular mechanism of Activin receptor inhibition by DLK1
Daniel Antfolk, Qianqian Ming, Anna Manturova, Erich J. Goebel, Thomas B. Thompson, Vincent C. Luca
Nature Communications.2025;[Epub] CrossRef

Diabetes, Obesity and Metabolism
Musclin Is Related to Insulin Resistance and Body Composition, but Not to Body Mass Index or Cardiorespiratory Capacity in Adults: Yeliana L. Sánchez, Manuela Yepes-Calderón, Luis Valbuena, Andrés F. Milán, María C. Trillos-Almanza, Sergio Granados, Miguel Peña, Mauricio Estrada-Castrillón, Juan C. Aristizábal, Raúl Narvez-Sanchez, Jaime Gallo-Villegas, Juan C. Calderón; Endocrinol Metab. 2021;36(5):1055-1068. Published online October 21, 2021; DOI: https://doi.org/10.3803/EnM.2021.1104

9,769 View
155 Download
13 Web of Science
13 Crossref

Abstract PDF PubReader ePub

Background
We studied whether musclin function in humans is related to glycemic control, body composition, and cardiorespiratory capacity.
Methods
A cross-sectional study was performed in sedentary adults with or without metabolic syndrome (MS). Serum musclin was measured by enzyme-linked immunosorbent assay. Insulin resistance (IR) was evaluated by the homeostatic model assessment (HOMA-IR). Body composition was determined by dual-energy X-ray absorptiometry and muscle composition by measuring carnosine in the thigh, a surrogate of fiber types, through proton magnetic resonance spectroscopy. Cardiorespiratory capacity was assessed through direct ergospirometry.
Results
The control (n=29) and MS (n=61) groups were comparable in age (51.5±6.5 years old vs. 50.7±6.1 years old), sex (72.4% vs. 70.5% women), total lean mass (58.5%±7.4% vs. 57.3%±6.8%), and peak oxygen consumption (VO_peak) (31.0±5.8 mL O2./kg.min vs. 29.2±6.3 mL O2/kg.min). Individuals with MS had higher body mass index (BMI) (30.6±4.0 kg/m² vs. 27.4± 3.6 kg/m²), HOMA-IR (3.5 [95% confidence interval, CI, 2.9 to 4.6] vs. 1.7 [95% CI, 1.1 to 2.0]), and musclin (206.7 pg/mL [95% CI, 122.7 to 387.8] vs. 111.1 pg/mL [95% CI, 63.2 to 218.5]) values than controls (P˂0.05). Musclin showed a significant relationship with HOMA-IR (β=0.23; 95% CI, 0.12 to 0.33; P˂0.01), but not with VO_peak, in multiple linear regression models adjusted for age, sex, fat mass, lean mass, and physical activity. Musclin was significantly associated with insulin, glycemia, visceral fat, and regional muscle mass, but not with BMI, VCO2peak, maximum heart rate, maximum time of work, or carnosine.
Conclusion
In humans, musclin positively correlates with insulinemia, IR, and a body composition profile with high visceral adiposity and lean mass, but low body fat percentage. Musclin is not related to BMI or cardiorespiratory capacity.

Citations

Citations to this article as recorded by

Dynamic Response of Musclin, a Myokine, to Aerobic Exercise and Its Interplay With Natriuretic Peptides and Receptor C
Ji Sun Nam, Eun-Suk Cho, Yu Rim Kwon, Jong Suk Park, YuSik Kim
The Journal of Clinical Endocrinology & Metabolism.2025; 110(5): 1305. CrossRef
Relationship between myostatin, musclin, nutritional status, and functionality in older Colombian community-dwelling adults: A cross-sectional study
Nancy Marulanda-Díaz, Alejandro Estrada-Restrepo, Andrés F. Milán, Raul Narvaez-Sanchez, Juan C. Calderón, Nubia A. Giraldo-Giraldo
Nutrition.2025; 135: 112767. CrossRef
Response to Letter to the Editor From Prickett and Espiner: “Dynamic Response of Musclin, a Myokine, to Aerobic Exercise and Its Interplay With Natriuretic Peptides and Receptor C”
YuSik Kim
The Journal of Clinical Endocrinology & Metabolism.2025; 110(5): e1716. CrossRef
Myonectin and metabolic health: a systematic review
Jorge L. Petro, Jaime Gallo-Villegas, Juan C. Calderón
Frontiers in Endocrinology.2025;[Epub] CrossRef
Myokine-mediated muscle-organ interactions: Molecular mechanisms and clinical significance
Jia Yi, Junyang Chen, Xinlei Yao, Zihao Zhao, Xinxin Niu, Xia Li, Jiacheng Sun, Yanan Ji, Tongxin Shang, Leilei Gong, Bingqian Chen, Hualin Sun
Biochemical Pharmacology.2025; 242: 117326. CrossRef
Musclin Mitigates the Attachment of HUVECs to THP-1 Monocytes in Hyperlipidemic Conditions through PPARα/HO-1-Mediated Attenuation of Inflammation
Wonjun Cho, Heeseung Oh, Sung Woo Choi, A. M. Abd El-Aty, Fatma Yeşilyurt, Ji Hoon Jeong, Tae Woo Jung
Inflammation.2024; 47(1): 1. CrossRef
Glucose restriction enhances oxidative fiber formation: A multi-omic signal network involving AMPK and CaMK2
Kaiyi Zhang, Ning Xie, Huaqiong Ye, Jiakun Miao, Boce Xia, Yu Yang, Huanqi Peng, Shuang Xu, Tianwen Wu, Cong Tao, Jinxue Ruan, Yanfang Wang, Shulin Yang
iScience.2024; 27(1): 108590. CrossRef
Myokines: metabolic regulation in obesity and type 2 diabetes
Zhi-Tian Chen, Zhi-Xuan Weng, Jiandie D Lin, Zhuo-Xian Meng
Life Metabolism.2024;[Epub] CrossRef
Epidemiological, mechanistic, and practical bases for assessment of cardiorespiratory fitness and muscle status in adults in healthcare settings
Jaime A. Gallo-Villegas, Juan C. Calderón
European Journal of Applied Physiology.2023; 123(5): 945. CrossRef
Serum Levels of Myonectin Are Lower in Adults with Metabolic Syndrome and Are Negatively Correlated with Android Fat Mass
Jorge L. Petro, María Carolina Fragozo-Ramos, Andrés F. Milán, Juan C. Aristizabal, Jaime A. Gallo-Villegas, Juan C. Calderón
International Journal of Molecular Sciences.2023; 24(8): 6874. CrossRef
The correlation of serum musclin with diabetic nephropathy
Jie Zhang, Jing Shi, Zengguang Cheng, Wenchao Hu
Cytokine.2023; 167: 156211. CrossRef
Efficacy of high-intensity interval- or continuous aerobic-training on insulin resistance and muscle function in adults with metabolic syndrome: a clinical trial
Jaime Gallo-Villegas, Leonardo A. Castro-Valencia, Laura Pérez, Daniel Restrepo, Oscar Guerrero, Sergio Cardona, Yeliana L. Sánchez, Manuela Yepes-Calderón, Luis H. Valbuena, Miguel Peña, Andrés F. Milán, Maria C. Trillos-Almanza, Sergio Granados, Juan C.
European Journal of Applied Physiology.2022; 122(2): 331. CrossRef
Reactive Oxygen and Nitrogen Species (RONS) and Cytokines—Myokines Involved in Glucose Uptake and Insulin Resistance in Skeletal Muscle
Paola Llanos, Jesus Palomero
Cells.2022; 11(24): 4008. CrossRef

Diabetes, Obesity and Metabolism
Role of TRPV4 Channel in Human White Adipocytes Metabolic Activity: Julio C. Sánchez, Aníbal Valencia-Vásquez, Andrés M. García; Endocrinol Metab. 2021;36(5):997-1006. Published online October 14, 2021; DOI: https://doi.org/10.3803/EnM.2021.1167

7,291 View
147 Download
7 Web of Science
7 Crossref

Abstract PDF PubReader ePub

Background
Intracellular calcium (Ca²⁺) homeostasis plays an essential role in adipocyte metabolism and its alteration is associated with obesity and related disorders. Transient receptor potential vanilloid 4 (TRPV4) channels are an important Ca²⁺ pathway in adipocytes and their activity is regulated by metabolic mediators such as insulin. In this study, we evaluated the role of TRPV4 channels in metabolic activity and adipokine secretion in human white adipocytes.
Methods
Human white adipocytes were freshly cultured and the effects of the activation and inhibition of TRPV4 channels on lipolysis, glucose uptake, lactate production, and leptin and adiponectin secretion were evaluated.
Results
Under basal and isoproterenol-stimulated conditions, TRPV4 activation by GSK1016709A decreased lipolysis whereas HC067047, an antagonist, increased lipolysis. The activation of TRPV4 resulted in increased glucose uptake and lactate production under both basal conditions and insulin-stimulated conditions; in contrast HC067047 decreased both parameters. Leptin production was increased, and adiponectin production was diminished by TRPV4 activation and its inhibition had the opposite effect.
Conclusion
Our results suggested that TRPV4 channels are metabolic mediators involved in proadipogenic processes and glucose metabolism in adipocyte biology. TRPV4 channels could be a potential pharmacological target to treat metabolic disorders.

Citations

Citations to this article as recorded by

Comparative Hypothalamic Proteomic Analysis Between Diet-Induced Obesity and Diet-Resistant Rats
Pengjiao Xi, Shuhui Ma, Derun Tian, Yanna Shen
International Journal of Molecular Sciences.2025; 26(5): 2296. CrossRef
Obesity, bone marrow adiposity, and leukemia: Time to act
Vijay Kumar, John H. Stewart
Obesity Reviews.2024;[Epub] CrossRef
TRP channels associated with macrophages as targets for the treatment of obese asthma
Wenzhao Zhu, Dinxi Bai, Wenting Ji, Jing Gao
Lipids in Health and Disease.2024;[Epub] CrossRef
Multidisciplinary Advances Address the Challenges in Developing Drugs against Transient Receptor Potential Channels to Treat Metabolic Disorders
Yibing Wang
ChemMedChem.2023;[Epub] CrossRef
Ion channels regulate energy homeostasis and the progression of metabolic disorders: Novel mechanisms and pharmacology of their modulators
Wenyi Wu, Jianan Zheng, Ru Wang, Yibing Wang
Biochemical Pharmacology.2023; 218: 115863. CrossRef
Potential lipolytic regulators derived from natural products as effective approaches to treat obesity
Xi-Ding Yang, Xing-Cheng Ge, Si-Yi Jiang, Yong-Yu Yang
Frontiers in Endocrinology.2022;[Epub] CrossRef
Adipokines: Deciphering the cardiovascular signature of adipose tissue
Joseph C. Galley, Shubhnita Singh, Wanessa M.C. Awata, Juliano V. Alves, Thiago Bruder-Nascimento
Biochemical Pharmacology.2022; 206: 115324. CrossRef

Review Article

Obesity and Metabolism
Role of PCSK9 Inhibitors in Patients with Familial Hypercholesterolemia: Brian Tomlinson, Nivritti Gajanan Patil, Manson Fok, Christopher Wai Kei Lam; Endocrinol Metab. 2021;36(2):279-295. Published online April 19, 2021; DOI: https://doi.org/10.3803/EnM.2021.964

13,665 View
377 Download
21 Web of Science
22 Crossref

Abstract PDF PubReader ePub

Patients with familial hypercholesterolemia (FH) are at high or very high risk for cardiovascular disease. Those with heterozygous FH (HeFH) often do not reach low-density lipoprotein cholesterol (LDL-C) targets with statin and ezetimibe therapy, and those with homozygous FH (HoFH) usually require additional lipid-modifying therapies. Drugs that inhibit proprotein convertase subtilisin/kexin type 9 (PCSK9) offer a novel approach to reduce LDL-C. The monoclonal antibodies, alirocumab and evolocumab, given by subcutaneous injection every 2 or 4 weeks produce reductions in LDL-C of 50% to 60% in patients with HeFH, allowing many of them to achieve their LDL-C goals. Patients with HoFH show a reduced and more variable LDL-C response, which appears to depend on residual LDL receptor activity, and those with receptor-negative mutations may show no response. Inclisiran is a long-acting small interfering RNA therapeutic agent that inhibits the synthesis of PCSK9. Subcutaneous doses of 300 mg can reduce LDL-C by more than 50% for at least 6 months and the responses in HeFH and HoFH patients are similar to those achieved with monoclonal antibodies. These PCSK9 inhibitors are generally well tolerated and they provide a new opportunity for effective treatment for the majority of patients with FH.

Citations

Citations to this article as recorded by

The pleomorphic cholesterol sensing motifs of transmembrane proteins
Francisco J. Barrantes
Chemistry and Physics of Lipids.2025; 266: 105460. CrossRef
Therapeutic target prediction for orphan diseases integrating genome-wide and transcriptome-wide association studies
Satoko Namba, Michio Iwata, Shin-Ichi Nureki, Noriko Yuyama Otani, Yoshihiro Yamanishi
Nature Communications.2025;[Epub] CrossRef
(−)-Oleuropein as a Novel Metastatic Castration-Resistant Prostate Cancer Progression and Recurrence Suppressor via Targeting PCSK9-LDLR Axis
Nehal A. Ahmed, Mohamed M. Mohyeldin, Hassan Y. Ebrahim, Oliver C. McGehee, Md Towhidul Islam Tarun, Khalid A. El Sayed
Nutrients.2025; 17(9): 1445. CrossRef
A Decade of FDA-Approved Pharmacophore-Based Small Molecules: Advances in Medicinal Chemistry from 2014 to 2024
Randhe Siddhant Sanjaykumar, Chavan Sagar Basavaraj, Anam Sania Md. Arshad, Rohit Singh, Neeraj Mahindroo
Synlett.2025; 36(16): 2499. CrossRef
Lipids and Inflammation: Novel Molecular Targets and Therapeutic Implications
Laura Torlai Triglia, Filippo Luca Gurgoglione, Federico Barocelli, Michele Bianconcini, Giampaolo Niccoli
Current Medicinal Chemistry.2025; 32(15): 2950. CrossRef
Inhibition of PCSK9 Improves the Development of Pulmonary Arterial Hypertension Via Down-Regulating Notch3 Expression
Peng Ye, Xiao-Min Jiang, Wei-Chun Qian, Juan Zhang
Cardiovascular Drugs and Therapy.2024; 38(6): 1223. CrossRef
Long-term safety and effectiveness of alirocumab and evolocumab in familial hypercholesterolemia (FH) in Belgium
Marc Snel, Olivier S. Descamps
Acta Cardiologica.2024; 79(3): 311. CrossRef
Phenotypic homozygous familial hypercholesterolemia successfully treated with proprotein convertase subtilisin/kexin type 9 inhibitors
Ryosuke Tani, Keiji Matsunaga, Yuta Toda, Tomoko Inoue, Hai Ying Fu, Tetsuo Minamino
Clinical Case Reports.2024;[Epub] CrossRef
Targeting Lipoprotein(a): Can RNA Therapeutics Provide the Next Step in the Prevention of Cardiovascular Disease?
Henriette Thau, Sebastian Neuber, Maximilian Y. Emmert, Timo Z. Nazari-Shafti
Cardiology and Therapy.2024; 13(1): 39. CrossRef
Technologies of gene editing and related clinical trials for the treatment of genetic and acquired diseases: a systematic review
Wessam Sharaf-Eldin
Egyptian Journal of Medical Human Genetics.2024;[Epub] CrossRef
Hypercholesterolemia: a literature review on management using tafolecimab: a novel member of PCSK9 monoclonal antibodies
Zaheer Qureshi, Mikail Khanzada, Adnan Safi, Eeshal Fatima, Faryal Altaf, Timothy J. Vittorio
Annals of Medicine & Surgery.2024; 86(5): 2818. CrossRef
Recurrent Acute Coronary Syndrome in Young Man with Familial Hypercholesterolemia: Efficacy of Evolocumab Add-On Treatment Demonstrated via Serial Coronary Angiography
Narae Kim, Jin-Man Cho, In-Ho Yang
Biomedicines.2024; 12(5): 1113. CrossRef
Qualitative and Quantitative Effects of PCSK9 Inhibitors in familial Hypercholesterolemia: a Synthetic Review
Aamina Shakir, Kyle Barron, Kalgi Modi
Current Problems in Cardiology.2023; 48(4): 101550. CrossRef
Barriers and shortcomings in access to cardiovascular management and prevention for familial hypercholesterolemia during the COVID‐19 pandemic
Helen Huang, Keith S. K. Leung, Tulika Garg, Adele Mazzoleni, Goshen D. Miteu, Farida Zakariya, Wireko A. Awuah, Elaine T. S. Yin, Faaraea Haroon, Zarish Hussain, Narjiss Aji, Vikash Jaiswal, Gary Tse
Clinical Cardiology.2023; 46(8): 831. CrossRef
Familial Hypercholesterolemia in Children. The Current State of the Problem
Dinara I. Sadykova, Karina R. Salakhova, Liliya F. Galimova, Eugeniya S. Slastnikova, Chulpan D. Khaliullina
Current Pediatrics.2023; 22(3): 231. CrossRef
PCSK9 inhibitors revisited: Effectiveness and safety of PCSK9 inhibitors in a real-life Spanish cohort
Juan Vicente-Valor, Xandra García-González, Sara Ibáñez-García, María Esther Durán-García, Ana de Lorenzo-Pinto, Carmen Rodríguez-González, Irene Méndez-Fernández, Juan Carlos Percovich-Hualpa, Ana Herranz-Alonso, María Sanjurjo-Sáez
Biomedicine & Pharmacotherapy.2022; 146: 112519. CrossRef
Development of small-molecule PCSK9 inhibitors for the treatment of hypercholesterolemia
Shakir Ahamad, Shintu Mathew, Waqas A. Khan, Kishor Mohanan
Drug Discovery Today.2022; 27(5): 1332. CrossRef
The biological relevance of PCSK9: when less is better…
Majambu Mbikay, Michel Chrétien
Biochemistry and Cell Biology.2022; 100(3): 189. CrossRef
Fenofibrate add-on to statin treatment is associated with low all-cause death and cardiovascular disease in the general population with high triglyceride levels
Kyung-Soo Kim, Sangmo Hong, Kyungdo Han, Cheol-Young Park
Metabolism.2022; 137: 155327. CrossRef
Homozygous Familial Hypercholesterolemia
Lisa Young, Emily E. Brown, Seth S. Martin
JACC: Case Reports.2022; 4(23): 101666. CrossRef
Familial Hypercholesterolemia and Its Current Diagnostics and Treatment Possibilities: A Literature Analysis
Kristina Zubielienė, Gintarė Valterytė, Neda Jonaitienė, Diana Žaliaduonytė, Vytautas Zabiela
Medicina.2022; 58(11): 1665. CrossRef
Efficacy and Safety of Alirocumab in Children and Adolescents With Homozygous Familial Hypercholesterolemia: Phase 3, Multinational Open-Label Study
Eric Bruckert, Sonia Caprio, Albert Wiegman, Min-Ji Charng, Cézar A. Zárate-Morales, Marie T. Baccara-Dinet, Garen Manvelian, Anne Ourliac, Michel Scemama, Stephen R. Daniels
Arteriosclerosis, Thrombosis, and Vascular Biology.2022; 42(12): 1447. CrossRef

Original Article

Clinical Study
Efficacy and Safety of the Novel Dipeptidyl Peptidase-4 Inhibitor Gemigliptin in the Management of Type 2 Diabetes: A Meta-Analysis: Deep Dutta, Anshita Agarwal, Indira Maisnam, Rajiv Singla, Deepak Khandelwal, Meha Sharma; Endocrinol Metab. 2021;36(2):374-387. Published online April 6, 2021; DOI: https://doi.org/10.3803/EnM.2020.818

11,767 View
272 Download
34 Web of Science
37 Crossref

Abstract PDF Supplementary Material PubReader ePub

Background
No meta-analysis has holistically analysed and summarised the efficacy and safety of gemigliptin in type 2 diabetes. The meta-analysis addresses this knowledge gap.
Methods
Electronic databases were searched for randomised controlled trials (RCTs) involving diabetes patients receiving gemigliptin in the intervention arm and placebo/active comparator in the control arm. The primary outcome was change in haemoglobin A1c (HbA1c). The secondary outcomes were alterations in glucose, glycaemic targets, lipids, insulin resistance, and adverse events.
Results
Data from 10 RCTs involving 1,792 patients were analysed. Four had an active control group (ACG), with metformin/dapagliflozin/sitagliptin/glimepiride as the active comparator; six had a passive control group (PCG), with placebo/rosuvastatin as controls. HbA1c reduction by gemigliptin at 24 weeks was comparable to ACG (mean difference [MD], 0.09%; 95% confidence interval [CI], –0.06 to 0.23; P=0.24; I²=0%; moderate certainty of evidence [MCE]), but superior to PCG (MD, –0.91%; 95% CI, –1.18 to –0.63); P<0.01; I²=89%; high certainty of evidence [HCE]). Gemigliptin was superior to PCG regarding achieving HbA1c <7% (12 weeks: odds ratio [OR], 5.91; 95% CI, 1.34 to 26.08; P=0.02; I²=74%; 24 weeks: OR, 4.48; 95% CI, 2.09 to 9.60; P<0.01; I²=69%; HCE). Gemigliptin was comparable to ACG regarding achieving HbA1c <7% after 24 weeks (OR, 0.92; 95% CI, 0.52 to 1.63; P=0.77; I²=66%; MCE). Adverse events were similar between the gemigliptin and control groups (risk ratio [RR], 1.06; 95% CI, 0.82 to 1.36; P=0.66; I²=35%; HCE). The gemigliptin group did not have increased hypoglycaemia (RR, 1.19; 95% CI, 0.62 to 2.28; P=0.61; I²=19%; HCE).
Conclusion
Gemigliptin has good glycaemic efficacy and is well-tolerated over 6 months of use.

Citations

Citations to this article as recorded by

Efficacy and safety of the glucagon receptor antagonist volagidemab in type‐1 diabetes: A systematic review and meta‐analysis
Deep Dutta, A. B. M. Kamrul‐Hasan, Vineet Surana, Rajiv Singla, Deepak Khandelwal, Sameer Aggarwal, Lakshmi Nagendra, Saptarshi Bhattacharya
Annals of the New York Academy of Sciences.2025; 1543(1): 94. CrossRef
Optimal Use of Once-Weekly Basal Insulin Efsitora Alfa in Type 1 and Type 2 Diabetes: A Systematic Review and Meta-Analysis
Deep Dutta, Lakshmi Nagendra, Manoj Kumar, A.B.M. Kamrul-Hasan, Saptarshi Bhattacharya
Endocrine Practice.2025; 31(4): 471. CrossRef
Efficacy and Safety of Tocilizumab in Polymyalgia Rheumatica: A Systematic Review and Meta‐Analysis
Meha Sharma, Siddharth Kumar Das, Ritin Mohindra, Deep Dutta
International Journal of Rheumatic Diseases.2025;[Epub] CrossRef
Safety of Rapid Intermittent Bolus versus Slow Continuous Infusion of Hypertonic Saline for Managing Symptomatic Severe Hyponatremia: A Systematic Review and Meta-analysis
Deep Dutta, Manoj Kumar, Ameya Joshi, Meha Sharma
Annals of African Medicine.2025; 24(2): 431. CrossRef
Cardiovascular safety of gabapentinoids gabapentin & pregabalin: A systematic review
Deep Dutta, Ritin Mohindra, Manoj Kumar, Mainak Banerjee, Meha Sharma, Satinath Mukhopadhyay
The Indian Journal of Medical Research.2025; 161: 363. CrossRef
Efficacy and Safety of Twincretin Survodutide, a Dual Glucagon-Like Peptide-1 and Glucagon Receptor Agonist as an Anti-Obesity and Anti-Diabetes Medication: A Systematic Review and Meta-Analysis
Deep Dutta, Abul B. M. Kamrul-Hasan, Ameya Joshi, Anil Dhall, Lakshmi Nagendra, Meha Sharma
Indian Journal of Endocrinology and Metabolism.2025; 29(3): 253. CrossRef
Hyperprolactinemia Due to Prolactinoma has an Adverse Impact on Bone Health with Predominant Impact on Trabecular Bone: A Systematic Review and Meta-Analysis
Lakshmi Nagendra, Deep Dutta, Sunetra Mondal, Nitin Kapoor, Ameya Joshi, Saptarshi Bhattacharya
Journal of Clinical Densitometry.2024; 27(1): 101453. CrossRef
Impact of early initiation of ezetimibe in patients with acute coronary syndrome: A systematic review and meta-analysis
Kunal Mahajan, Lakshmi Nagendra, Anil Dhall, Deep Dutta
European Journal of Internal Medicine.2024; 124: 99. CrossRef
Efficacy and safety of dorzagliatin, a novel glucokinase activators, in the treatment of T2DM: A meta-analysis of randomized controlled trials
Yuqian Wu, Kai Wang, Jingyang Su, Xin Liu
Medicine.2024; 103(8): e36916. CrossRef
Glucagon-Like Peptide-1 Receptor Agonists in Post-bariatric Surgery Patients: A Systematic Review and Meta-analysis
Deep Dutta, Lakshmi Nagendra, Ameya Joshi, Suryashri Krishnasamy, Meha Sharma, Naresh Parajuli
Obesity Surgery.2024; 34(5): 1653. CrossRef
Orforglipron, a novel non‐peptide oral daily glucagon‐like peptide‐1 receptor agonist as an anti‐obesity medicine: A systematic review and meta‐analysis
Deep Dutta, Lakshmi Nagendra, Beatrice Anne, Manoj Kumar, Meha Sharma, A. B. M. Kamrul‐Hasan
Obesity Science & Practice.2024;[Epub] CrossRef
Safety and tolerability of sodium-glucose cotransporter-2 inhibitors in children and young adults: a systematic review and meta-analysis
Lakshmi Nagendra, Deep Dutta, Harish Bukkasagar Girijashankar, Deepak Khandelwal, Tejal Lathia, Meha Sharma
Annals of Pediatric Endocrinology & Metabolism.2024; 29(2): 82. CrossRef
Impact of Pheochromocytoma or Paraganglioma on Bone Metabolism: A Systemic Review and Meta-analysis
Deep Dutta, Lakshmi Nagendra, Manju Chandran, Meha Sharma, Saptarshi Bhattacharya, Satinath Mukhopadhyay
Journal of Clinical Densitometry.2024; 27(3): 101501. CrossRef
Long-Term Impact on Offspring (5 to 11 Years of Age) of Metformin Use in Pregnancy in Mothers With Diabetes: A Systematic Review and Meta-Analysis
Deep Dutta, Meha Sharma, Lakshmi Nagendra, Saptarshi Bhattacharya, Ritin Mohindra, Chittaranjan S. Yajnik
Endocrine Practice.2024; 30(9): 854. CrossRef
Efficacy and Safety of Osilodrostat in Managing Cushing’s Syndrome: A Systematic Review and Meta-Analysis
Lakshmi Nagendra, Deep Dutta, Nishant Raizada, Vineet Surana, Chitra Selvan, Saptarshi Bhattacharya
Indian Journal of Endocrinology and Metabolism.2024; 28(3): 232. CrossRef
Efficacy and Safety of Cagrilintide Alone and in Combination with Semaglutide (Cagrisema) as Anti-Obesity Medications: A Systematic Review and Meta-Analysis
Deep Dutta, Lakshmi Nagendra, BG Harish, Meha Sharma, Ameya Joshi, Basavanagowdappa Hathur, ABM Kamrul-Hasan
Indian Journal of Endocrinology and Metabolism.2024; 28(5): 436. CrossRef
Gender differences in the management and outcomes of acute coronary syndrome in indians: A systematic review and meta-analysis
Deep Dutta, Kunal Mahajan, Lokesh Verma, Gunjan Gupta, Meha Sharma
Indian Heart Journal.2024; 76(5): 333. CrossRef
Efficacy and safety of novel dual glucokinase activator dorzagliatin in type-2 diabetes A meta-analysis
Deep Dutta, Deepak Khandelwal, Manoj Kumar, Meha Sharma
Diabetes & Metabolic Syndrome: Clinical Research & Reviews.2023; 17(1): 102695. CrossRef
Efficacy and safety of novel thiazolidinedione lobeglitazone for managing type-2 diabetes a meta-analysis
Deep Dutta, Saptarshi Bhattacharya, Manoj Kumar, Priyankar K. Datta, Ritin Mohindra, Meha Sharma
Diabetes & Metabolic Syndrome: Clinical Research & Reviews.2023; 17(1): 102697. CrossRef
Effects of Initial Combinations of Gemigliptin Plus Metformin Compared with Glimepiride Plus Metformin on Gut Microbiota and Glucose Regulation in Obese Patients with Type 2 Diabetes: The INTESTINE Study
Soo Lim, Minji Sohn, Jose C. Florez, Michael A. Nauck, Jiyoung Ahn
Nutrients.2023; 15(1): 248. CrossRef
Systematic review and meta-analysis of teneligliptin for treatment of type 2 diabetes
R. Pelluri, S. Kongara, V. R. Nagasubramanian, S. Mahadevan, J. Chimakurthy
Journal of Endocrinological Investigation.2023; 46(5): 855. CrossRef
Efficacy and safety of enavogliflozin versus dapagliflozin added to metformin plus gemigliptin treatment in patients with type 2 diabetes: A double-blind, randomized, comparator-active study: ENHANCE-D study
Kyung-Soo Kim, Kyung Ah Han, Tae Nyun Kim, Cheol-Young Park, Jung Hwan Park, Sang Yong Kim, Yong Hyun Kim, Kee Ho Song, Eun Seok Kang, Chul Sik Kim, Gwanpyo Koh, Jun Goo Kang, Mi Kyung Kim, Ji Min Han, Nan Hee Kim, Ji Oh Mok, Jae Hyuk Lee, Soo Lim, Sang S
Diabetes & Metabolism.2023; 49(4): 101440. CrossRef
Verapamil improves One-Year C-Peptide Levels in Recent Onset Type-1 Diabetes: A Meta-Analysis
Deep Dutta, Lakshmi Nagendra, Nishant Raizada, Saptarshi Bhattacharya, Meha Sharma
Indian Journal of Endocrinology and Metabolism.2023; 27(3): 192. CrossRef
Role of novel sodium glucose co-transporter-2 inhibitor enavogliflozin in type-2 diabetes: A systematic review and meta-analysis
Deep Dutta, B.G. Harish, Beatrice Anne, Lakshmi Nagendra
Diabetes & Metabolic Syndrome: Clinical Research & Reviews.2023; 17(8): 102816. CrossRef
Semaglutide and cancer: A systematic review and meta-analysis
Lakshmi Nagendra, Harish BG, Meha Sharma, Deep Dutta
Diabetes & Metabolic Syndrome: Clinical Research & Reviews.2023; 17(9): 102834. CrossRef
Efficacy and Safety of Novel Thiazolidinedione Rivoglitazone in Type-2 Diabetes a Meta-Analysis
Deep Dutta, Jyoti Kadian, Indira Maisnam, Ashok Kumar, Saptarshi Bhattacharya, Meha Sharma
Indian Journal of Endocrinology and Metabolism.2023; 27(4): 286. CrossRef
Impact of early initiation of proprotein convertase subtilisin/kexin type 9 inhibitors in patients with acute coronary syndrome: A systematic review meta-analysis
Lakshmi Nagendra, Kunal Mahajan, Gunjan Gupta, Deep Dutta
Indian Heart Journal.2023; 75(6): 416. CrossRef
Optimal use of once weekly icodec insulin in type-2 diabetes: An updated meta-analysis of phase-2 and phase-3 randomized controlled trials
Deep Dutta, Lakshmi Nagendra, Sowrabha Bhat, Ritin Mohindra, Vineet Surana, Anoop Misra
Diabetes & Metabolic Syndrome: Clinical Research & Reviews.2023; 17(10): 102877. CrossRef
Impact of Enhanced External Counter-pulsation Therapy on Glycaemic Control in People With Prediabetes and Type 2 Diabetes Mellitus: A Systematic Review and Meta-analysis
Lakshmi Nagendra, Deep Dutta, Meha Sharma, Harish Bg
touchREVIEWS in Endocrinology.2023; 19(2): 8. CrossRef
Role of Novel Glucagon-like Peptide-1 Receptor Analogue Polyethylene Glycol Loxenatide in Type 2 Diabetes: A Systematic Review and Meta-analysis
Deep Dutta, Subhankar Chatterjee, Priyankar K. Datta, Ritin Mohindra, Meha Sharma
Indian Journal of Endocrinology and Metabolism.2023; 27(5): 377. CrossRef
Efficacy and Safety of Ultra-rapid Lispro Insulin in Managing Type-1 and Type-2 Diabetes: A Systematic Review and Meta-Analysis
Deep Dutta, Lakshmi Nagendra, Saptarshi Bhattacharya, Meha Sharma
Indian Journal of Endocrinology and Metabolism.2023; 27(6): 467. CrossRef
Safety and efficacy of once weekly dipeptidyl-peptidase-4 inhibitor trelagliptin in type-2 diabetes: A meta-analysis
Deep Dutta, Ritin Mohindra, Vineet Surana, Meha Sharma
Diabetes & Metabolic Syndrome: Clinical Research & Reviews.2022; 16(4): 102469. CrossRef
Efficacy and safety of hydroxychloroquine for managing glycemia in type-2 diabetes: A systematic review and meta-analysis
D Dutta, R Jindal, D Mehta, M Kumar, M Sharma
Journal of Postgraduate Medicine.2022; 68(2): 85. CrossRef
Gemigliptin exerts protective effects against doxorubicin-induced hepatotoxicity by inhibiting apoptosis via the regulation of fibroblast growth factor 21 expression
Kyeong-Min Lee, Yeo Jin Hwang, Gwon-Soo Jung
Biochemical and Biophysical Research Communications.2022; 626: 135. CrossRef
Reporting and methodological quality of systematic reviews of DPP-4 inhibitors for patients with type 2 diabetes mellitus: an evidence-based mapping
Zouxi Du, Tingting Lu, Mingdong Gao, Limin Tian
Acta Diabetologica.2022; 59(12): 1539. CrossRef
Ranirestat Improves Electrophysiologic but not Clinical Measures of Diabetic Polyneuropathy
Deep Dutta, Ritin Mohindra, Manoj Kumar, Ashok Kumar, Meha Sharma
Indian Journal of Endocrinology and Metabolism.2022; 26(5): 399. CrossRef
Efficacy and safety of novel twincretin tirzepatide a dual GIP and GLP-1 receptor agonist in the management of type-2 diabetes: A Cochrane meta-analysis
Deep Dutta, Vineet Surana, Rajiv Singla, Sameer Aggarwal, Meha Sharma
Indian Journal of Endocrinology and Metabolism.2021; 25(6): 475. CrossRef

Review Article

Miscellaneous
Intraoperative Parathyroid Hormone Monitoring in the Surgical Management of Sporadic Primary Hyperparathyroidism: Zahra F. Khan, John I. Lew; Endocrinol Metab. 2019;34(4):327-339. Published online December 23, 2019; DOI: https://doi.org/10.3803/EnM.2019.34.4.327

11,656 View
215 Download
44 Web of Science
46 Crossref

Abstract PDF PubReader ePub

Intraoperative parathyroid hormone monitoring (IPM) has been shown to be a useful adjunct during parathyroidectomy to ensure operative success at many specialized medical centers worldwide. Using the Miami or “>50% intraoperative PTH drop” criterion, IPM confirms the complete excision of all hyperfunctioning parathyroid tissue before the operation is finished, and helps guide the surgeon to identify additional hyperfunctioning parathyroid glands that may necessitate further extensive neck exploration when intraoperative parathyroid hormone (PTH) levels do not drop sufficiently. The intraoperative PTH assay is also used to differentiate parathyroid from non-parathyroid tissues during operations using fine needle aspiration samples and to lateralize the side of the neck harboring the hypersecreting parathyroid through differential jugular venous sampling when preoperative localization studies are negative or equivocal. The use of IPM underscores the recognition and understanding of sporadic primary hyperparathyroidism (SPHPT) as a disease of function rather than form, where the surgeon is better equipped to treat such patients with quantitative instead of qualitative information for durable long-term operative success. There has been a significant paradigm shift over the last 2 decades from conventional to focused parathyroidectomy guided by IPM. This approach has proven to be a safe and rapid operation requiring minimal dissection performed in an ambulatory setting for the treatment of SPHPT.

Citations

Citations to this article as recorded by

Refining the role of presurgical PET/4D‐CT in a large series of patients with primary hyperparathyroidism undergoing [18F]Fluorocholine PET/CT
Ashjan Kaseb, Houda Benider, Giorgio Treglia, Caterina Cusumano, Darejan Bessac, Pierpaolo Trimboli, Michel Vix, Arnoldo Piccardo, Adrien Latgé, Alessio Imperiale
European Journal of Clinical Investigation.2025;[Epub] CrossRef
Intraoperative Parathyroid Hormone Kinetics are Variable: An In-Vivo Analysis
Antoinette R. Esce, Robert G. Nicholas, Noah P. Syme, Garth T. Olson, Nathan H. Boyd
Annals of Otology, Rhinology & Laryngology.2025; 134(2): 142. CrossRef
Intraoperative Parathyroid Hormone Monitoring Criteria in Primary Hyperparathyroidism
Phillip Staibano, Michael Au, Han Zhang, Sheila Yu, Winnie Liu, Jesse D. Pasternak, Xing Xing, Carolyn D. Seib, Lisa Orloff, Nhu-Tram Nguyen, Michael K. Gupta, Eric Monteiro, Sameer Parpia, Tyler McKechnie, Alex Thabane, J. E. M. (Ted) Young, Mohit Bhanda
JAMA Otolaryngology–Head & Neck Surgery.2025; 151(3): 190. CrossRef
Increase in serum parathyroid hormone level intraoperatively after parathyroidectomy for primary hyperparathyroidism
Bassam Abboud, Christopher Abboud
American Journal of Otolaryngology.2025; 46(2): 104598. CrossRef
Adenoma weight: the only predictive factor for multiple gland disease in primary hyperparathyroidism
Kirsten LINDNER, Jochen KUSSMANN, Volker FENDRICH, K. Alexander IWEN, Alexandra ZAHN
Minerva Endocrinology.2025;[Epub] CrossRef
Persistence and Recurrence of Primary Hyperparathyroidism
Rasha A.Y. Alnajmi, Dalal S. Ali, Aliya A. Khan
Best Practice & Research Clinical Endocrinology & Metabolism.2025; 39(2): 101986. CrossRef
Validation and implementation of an intraoperative parathyroid hormone assay and workflow: practical advice for endocrine surgery centres
Phillip Staibano, Basma Ahmed, Josko Ivica, Joseph Macri, Michael Au, Han Zhang, Jesse D. Pasternak, Mohit Bhandari, Peter Kavsak
Journal of Laboratory Medicine.2025; 49(3): 107. CrossRef
Unlocking the diagnostic potential of parathormone washout: a path to accurate parathyroid tumor localization
Ekin Yiğit Köroğlu, Berna Evranos Öğmen, Belma Tural Balsak, Mustafa Ömer Yazicioğlu, Cevdet Aydin, Oya Topaloğlu, Reyhan Ersoy, Bekir Çakir
Postgraduate Medicine.2025; 137(5): 439. CrossRef
Analysis of central and peripheral PTH decay values in patients with primary hyperparathyroidism
Giovanna Luiza Caxeiro, Davi Knoll Ribeiro, Rafael Dias Romero, Marcello Rosano, Rodrigo Oliveira Santos, Murilo Catafesta Neves, Marcio Abrahao
Brazilian Journal of Otorhinolaryngology.2025; 91: 101606. CrossRef
Differences in histopathologic features and diagnostic performance of 99mTc-methoxy-isobutyl-isonitrol single photon emission tomography–CT and 18F-fluorocholine positron emission tomography–CT in primary hyperparathyroidism
Irene Osorio-Silla, Diego Meneses González, Hernán Darío Quiceno Arias, Paula Pastor Peinado, Jersy Jair Cárdenas Salas, María Miguélez González, Carlos Augusto Pestana Soares, Luisa Fernanda Martínez Ruiz, Laura Cristina Landaeta Kancev, Luis Martínez Dh
Surgery.2025; 186: 109595. CrossRef
Diagnostic Accuracy of 4D CT in Detecting Parathyroid Adenoma Compared With Ultrasound and Sestamibi SPECT/CT in Primary Hyperparathyroidism: A Retrospective Study
Somdatta Giri, Krishnan Nagarajan, Balamourougan Krishnaraj, Debasis Gochhait, Madhusudhanan Ponnusamy, Anitha Sebastian, Baskararaj Sriviruthi, Jayaprakash Sahoo, Sadishkumar Kamalanathan, Dukhabandhu Naik
Cureus.2025;[Epub] CrossRef
Variable Presentations of Primary Hyperparathyroidism: an Experience of 5 Cases from a Tertiary-Care General Surgery Unit of Northern India
Sukesh Kudumallige Sudhakara, Urvij Jaiswal, Shubhajeet Roy, Kushagra Gaurav, Akshay Anand, Abhinav Arun Sonkar
Indian Journal of Otolaryngology and Head & Neck Surgery.2025; 77(12): 5373. CrossRef
Clinical Features and Management of Rare Giant Parathyroid Adenoma: A Case Series
Dhritiman Maitra, Kaustuv Das, Kaushik Mitra
Archives of Medicine and Health Sciences.2025; 13(2): 278. CrossRef
Predictors of Hungry Bone Syndrome After Parathyroidectomy in Secondary Hyperparathyroidism: A Narrative Review of Bone Turnover Biomarkers and Risk Prediction Tools
Adina Coman, Cristi Tarta, Alexandru Isaic, Marco Marian, Sorin Olariu, Andrei Ardelean, Anca-Monica Macovei-Oprescu, Fazakas Roland, Gheorghe-Nanu Pupca, Silviu Latcu, Cristian Silviu Suciu, Marius Murariu
Journal of Clinical Medicine.2025; 14(21): 7849. CrossRef
Advances in rapid parathyroid gland identification: clinical significance and emerging handheld imaging technologies
Yun Sung Lee, Jong Soo Kim, Seung Hoon Woo
Medical Lasers.2025; 14(3): 140. CrossRef
Intraoperative parathyroid hormone monitoring criteria in secondary and tertiary hyperparathyroidism: A systematic review
Phillip Staibano, Michael Au, Han Zhang, Jesse D. Pasternak, Carolyn D. Seib, Lisa Orloff, Xing Xing, Sheila Yu, Winnie Liu, Jason W. Busse, Sameer Parpia, Nhu-Tram Nguyen, Tyler McKechnie, Alex Thabane, J.E.M. (Ted) Young, Mohit Bhandari
Current Problems in Surgery.2025; 73: 101934. CrossRef
Chasing the Drop: Miami Versus Dual Criteria for Intraoperative Parathyroid Hormone Monitoring in Primary Hyperparathyroidism
Senthil Rajamanickam , Anurag Agarwal, Shruti Senthilkumar, Dimitrios Chatzoudis, Rachel Curran, Vignesh Balasubaramaniam, Shon Williams
Cureus.2025;[Epub] CrossRef
Thermal ablation for primary hyperparathyroidism: long-term follow-up results
RunZhe Wang, Xiao Yang, FeiHong Yu, BoQiang Fan
European Radiology.2025;[Epub] CrossRef
Improving Intraoperative Parathyroid Hormone Monitoring with a Multidisciplinary Checklist: A Quality Improvement Initiative
Austin R. Swisher, Justin M. Hintze, Chee‐Chee H. Stucky, Patricia A. Cronin, Payam Entezami, Michael L. Hinni, Brent A. Chang
Otolaryngology–Head and Neck Surgery.2025;[Epub] CrossRef
A >50% Intraoperative Parathyroid Hormone Level Decrease Into Normal Reference Range Predicts Complete Excision of Malignancy in Patients With Parathyroid Carcinoma
Valerie L. Armstrong, Tanaz M. Vaghaiwalla, Cima Saghira, Cheng-Bang Chen, Yujie Wang, Johan Anantharaj, Mehmet Ackin, John I. Lew
Journal of Surgical Research.2024; 300: 567. CrossRef
Intraoperative parathyroid hormone monitoring in parathyroidectomy for hyperparathyroidism: a protocol for a network meta-analysis of diagnostic test accuracy
Phillip Staibano, Kevin Um, Sheila Yu, Mohit Bhandari, Michael K. Gupta, Michael Au, JEM (Ted) Young, Han Zhang
Frontiers in Surgery.2024;[Epub] CrossRef
Primary Hyperparathyroidism
Saba Kurtom, Sally E. Carty
Surgical Clinics of North America.2024; 104(4): 799. CrossRef
Characteristics, management and outcomes of primary hyperparathyroidism from 2009 to 2021: a single centre report from South Africa
Kamal Govind, Imran M. Paruk, Ayesha A. Motala
BMC Endocrine Disorders.2024;[Epub] CrossRef
The significance of determining the Intraoperative level of parathormone during surgical treatment of hyperparathyroidism
Stefan Janičić, Kristina Stepanović, Mia Manojlović, Dean Bjelajac, Slađana Pejaković, Milan Mirković, Dragana Tomić-Naglić, Ivana Bajkin, Tijana Ičin
Hospital Pharmacology - International Multidisciplinary Journal.2024; 11(2): 1462. CrossRef
Revolutionizing parathyroid surgery: the impact of ultrafast intraoperative parathyroid hormone monitoring on patient outcomes
Ayush Anand, Ghomsi M.C. Nathalie, Obianuju Iheomamere Muoghallu, Prakasini Satapathy, Rakesh Kumar Sharma, Mahalaqua Nazli Khatib, Shilpa Gaidhane, Quazi Syed Zahiruddin, Sarvesh Rustagi, Kelechi Michael Azode
International Journal of Surgery Open.2024; 62(4): 534. CrossRef
A new approach for perioperative parathyroid hormone (PTH) measurement to establish cure in patients with primary hyperparathyroidism
Beatrice Sperotto, Natalie Meurer, Anke Meyer, Parviz Ahmad-Nejad, Norbert Bösing, Nadine Lange, Cornelia Dotzenrath, Pier Francesco Alesina
Langenbeck's Archives of Surgery.2024;[Epub] CrossRef
Parathyroidectomy for primary hyperparathyroidism: A retrospective analysis of localization, surgical characteristics, and treatment outcomes
Dongbin Ahn, Ji Hye Kwak, Gil Joon Lee, Jin Ho Sohn
Asian Journal of Surgery.2023; 46(2): 788. CrossRef
Magnitude of parathyroid hormone elevation in primary hyperparathyroidism: Does time of day matter?
C. Corbin Frye, Janessa Sullivan, Sai Anusha Sanka, Jingxia Liu, L. Michael Brunt, William Gillanders, Taylor C. Brown, T.K. Pandian
Surgery.2023; 173(3): 659. CrossRef
Analysis of intraoperative laboratory measurements and imaging techniques such as Tc-99 m-MIBI SPECT/CT, 18F-fluorocholine PET/CT and ultrasound in patients operated with prediagnosis of parathyroid adenoma
Nurullah Bilen, Mehmet Avni Gokalp, Latif Yilmaz, Alper Aytekin, Ilyas Baskonus
Irish Journal of Medical Science (1971 -).2023; 192(4): 1695. CrossRef
Intraoperative Parathyroid Hormone Monitoring Is of Limited Usefulness in Guiding Autotransplantation in Reoperative or Subtotal Parathyroidectomy for Primary Hyperparathyroidism
Bradley A. Richards, Robert A. Vierkant, Benzon M. Dy, Trenton R. Foster, Travis J. McKenzie, Melanie L. Lyden
The American Surgeon™.2023; 89(12): 5421. CrossRef
Does 18F-Fluorocholine PET/CT add value to positive parathyroid scintigraphy in the presurgical assessment of primary hyperparathyroidism?
Alessio Imperiale, Jacob Bani, Gianluca Bottoni, Adrien Latgé, Céline Heimburger, Ugo Catrambone, Michel Vix, Giorgio Treglia, Arnoldo Piccardo
Frontiers in Medicine.2023;[Epub] CrossRef
Intraoperative Identification of Thyroid and Parathyroid Tissues During Human Endocrine Surgery Using the MasSpec Pen
Rachel J. DeHoog, Mary E. King, Michael F. Keating, Jialing Zhang, Marta Sans, Clara L. Feider, Kyana Y. Garza, Alena Bensussan, Anna Krieger, John Q. Lin, Sunil Badal, Elizabeth Alore, Christopher Pirko, Kirtan Brahmbhatt, Wendong Yu, Raymon Grogan, Livi
JAMA Surgery.2023; 158(10): 1050. CrossRef
A Rare Case of Recurrent Parathyroid Adenomas After Initial Parathyroidectomy
Grant N Schalet, Luke Vincent, Carl Eguez, Gerardo Diaz, Mark S Shachner
Cureus.2023;[Epub] CrossRef
Surgical treatment of tertiary hyperparathyroidism: does one fit for all?
Claudio Casella, Claudio Guarneri, Manuela Campanile, Xavier Adhoute, Pier Paolo Gelera, Riccardo Morandi
Frontiers in Endocrinology.2023;[Epub] CrossRef
Variation in parathyroid adenoma size in patients with sporadic, primary hyperparathyroidism: small gland size does not preclude single gland disease
Sophie Dream, Tina W. F. Yen, Kara Doffek, Douglas B. Evans, Tracy S. Wang
Langenbeck's Archives of Surgery.2022; 407(5): 2067. CrossRef
Role and Recent Trend of Intraoperative Parathyroid Hormone Monitoring During Parathyroidectomy in Patients With Primary Hyperparathyroidism
Dongbin Ahn, Ji Hye Kwak
Korean Journal of Otorhinolaryngology-Head and Neck Surgery.2022; 65(5): 253. CrossRef
Parathyroid Adenoma: Rare Cause of Acute Recurrent Pancreatitis
Shikha Mahajan, Alka Kumar, Vivek Aggarwal, Vikas Jain, Vipul Baweja, Ajay Ajmani, Diplomate CBNC, Fellow EBNM LNU
Annals of Pediatric Gastroenterology and Hepatology.2022; 2(3-4): 9. CrossRef
Long-term outcome of surgical techniques for sporadic primary hyperparathyroidism in a tertiary referral center in Belgium
Klaas Van Den Heede, Amélie Bonheure, Nele Brusselaers, Sam Van Slycke
Langenbeck's Archives of Surgery.2022; 407(7): 3045. CrossRef
Contribution of intraoperative parathyroid hormone monitoring to the surgical success in minimal invasive parathyroidectomy
Ismail Ethem Akgün, Mehmet Taner Ünlü, Nurcihan Aygun, Mehmet Kostek, Mehmet Uludag
Frontiers in Surgery.2022;[Epub] CrossRef
Surgery for primary hyperparathyroidism
Murilo Catafesta das Neves, Rodrigo Oliveira Santos, Monique Nakayama Ohe
Archives of Endocrinology and Metabolism.2022; 66(5): 678. CrossRef
Використання інтраопераційного моніторингу рівня паратиреоїдного гормону в мінімально інвазивній хірургії щитоподібної та паращитоподібних залоз
S.V. Chernyshov, A.V. Tymkiv, A.V. Vovkanych, I.I. Komisarenko
Endokrynologia.2022; 27(4): 311. CrossRef
Diagnostic Values of Intraoperative (1-84) Parathyroid Hormone Levels are Superior to Intact Parathyroid Hormone for Successful Parathyroidectomy in Patients With Chronic Kidney Disease
Fangyan Xu, Yaoyu Huang, Ming Zeng, Lina Zhang, Wenkai Ren, Hanyang Qian, Ying Cui, Guang Yang, Wenbin Zhou, Shui Wang, Hui Huang, Huimin Chen, Yujie Xiao, Xueyan Gao, Zhanhui Gao, Jing Wang, Cuiping Liu, Jing Zhang, Baiqiao Zhao, Anning Bian, Fan Li, Hui
Endocrine Practice.2021; 27(11): 1065. CrossRef
Delayed Calcium Normalization after Successful Parathyroidectomy in Primary Hyperparathyroidism
Iván Emilio de la Cruz Rodríguez, Elsy Sarahí García Montesinos, María Fernanda Rodríguez-Delgado, Guadalupe Vargas Ortega, Lourdes Balcázar Hernández, Victoria Mendoza Zubieta, Victor Hernández Avendaño, Baldomero González Virla, Michaï¿½l R. Laurent
Case Reports in Endocrinology.2021;[Epub] CrossRef
Parathyroid Surgery
Aditya S. Shirali, Uriel Clemente-Gutierrez, Nancy D. Perrier
Neuroimaging Clinics of North America.2021; 31(3): 397. CrossRef
Focused parathyroidectomy without intraoperative parathyroid hormone measurement in primary hyperparathyroidism: Still a valid approach?
Shelby Holt
Surgery.2021; 170(6): 1860. CrossRef
Response to the Comment on “Risk Factors of Redo Surgery After Unilateral Focused Parathyroidectomy – Conclusions From a Comprehensive Nationwide Database of 13,247 Interventions Over 6 Years”
Robert Caiazzo, Camille Marciniak, Francois Pattou
Annals of Surgery.2021; 274(6): e861. CrossRef

Original Articles

Effects of Interleukin-6 on mRNA Expression of Alkaline Phosphatase, Osteopontin, Decorin and a1(1)-collagen in Human Bone Marrow Stromal Cells.: Chul Hee Kim, Dong Kwan Kim, Seung Il Park, Kwang Hyun Sohn, Ghi Su Kim; J Korean Endocr Soc. 1996;11(2):156-162. Published online November 7, 2019

1,584 View
25 Download

Abstract PDF: Background
Inter1eukin-6(IL-6) is known to be produced by osteoblastic cells and to have impartant role in regulation of bone remodelling, Most previous studies indicated that IL-6 bas a major role in stimulating osteoclastic resorption by increasing recruitment and proliferation of preosteoclasts. But its autocrine effect on osteoblastic cells has not been well established yet. Therefore, we studied the effects of IL-6 on messenger RNA (mRNA) expression of proteins that are characteristic of osteoblastic cells in human bone marrow stromal (osteoprogenitor) cells (hRMSC). Methods: The expression of mRNAs for alkaline phosphatase, al(1)-collagen, osteopontin and decorin were studied by northern blot analysis after 3 7 days' treatrnent with IL-6 in the concenttation range of 101,000 U/ml. Results: The mRNA levels for any of the osteoblastic proteins studied did not change significantly by IL-6 treatment up to the concentration of 1,000 U/ml. Conclusion: These results suggest that IL-6 does not have a significant role in differentiatian or activities of human bone rnarrow stromal.

Clinical Effects of E. coli Derived Recombinant Human Growth Hormone (DA - 3001) in Patients with Growth Hormone Deficiency.: Sei Won Yang, Jeh Hoon Shin, Duk Hi Kim, Byung Churl Lee, Hyung Ro Moon; J Korean Endocr Soc. 1995;10(4):377-385. Published online November 7, 2019

1,854 View
32 Download

Abstract PDF: Recently, methionyl-hGH was produced in the E. coil K-12, W3110 by recombinant DNA technology in Korea. In this paper, the clinical efficacy and immunogenicity of this GH were studied in 43 patients with growth hormone deficency.The subjects of this study were aged 4.3-18.5 years and each patient received GH 0.5-0.71U/kg week subcutaneously, 6-7 times a week for 1 year. During treatment, height, body weight and bone age were checked. Blood count, urinalysis, blood chemistry and thyroid hormonal concentrations were checked before and every 3 months. The measurement of IGF-1 was performed and assay of antibody against hGH was performed before and every 6 months.The height velocities significantly increased from 3.7+-3.0 cm/year to 11.0+-4.2 cm/year and 9.9+-3.2 cm/year at 6 and 12 months after GH therapy, respectively. The Height SDS were significantly improved after GH therapy with increasing ratio of bone age to chronological age from 0.60+-0.19 at pretreatment to 0.68+-0.16 at 6 month, 0.69+-0.16 at 12 month of therapy. The plasma IGF-1 levels significantly increased during treatment. Three out of 35 patients(8.3%) showed antibody against hGH after 1 year of treatment. Thoughout study, we could not observe any remarkable side effect with GH treatment.These results indicate that this E. coli derived methionyl recombinant growth hormone is effective in improving the index of linear growth in the children with growth hormone deficiency without significant side effect.

Clinical Study
Effects of Maternal Iodine Status during Pregnancy and Lactation on Maternal Thyroid Function and Offspring Growth and Development: A Prospective Study Protocol for the Ideal Breast Milk Cohort: Young Ah Lee, Sun Wook Cho, Ho Kyung Sung, Kyungsik Kim, Young Shin Song, Sin Je Moon, Jung Won Oh, Dal Lae Ju, Sooyeon Choi, Sang Hoon Song, Gi Jeong Cheon, Young Joo Park, Choong Ho Shin, Sue K. Park, Jong Kwan Jun, June-Key Chung; Endocrinol Metab. 2018;33(3):395-402. Published online September 18, 2018; DOI: https://doi.org/10.3803/EnM.2018.33.3.395

8,743 View
105 Download
4 Web of Science
4 Crossref

Abstract PDF PubReader ePub

Background

Iodine is an intrinsic element of thyroid hormone, which is essential for childhood growth and development. The Ideal Breast Milk (IBM) cohort study aims to evaluate the effects of maternal iodine status during pregnancy and lactation on maternal thyroid function, offspring growth and development, and offspring thyroid function.

Methods

The IBM cohort study recruited pregnant women from Seoul National University Hospital between June 2016 and August 2017, followed by enrollment of their offspring after delivery. For the maternal participants, iodine status is evaluated by urinary iodine concentration (UIC) and dietary records in the third trimester and at 3 to 4 weeks and 12 to 15 months postpartum. For the child participants, cord blood sampling and UIC measurements are performed at birth. At 3 to 4 weeks of age, UIC and breastmilk iodine concentrations are measured. At 12 to 15 months of age, growth and development are assessed and measurements of UIC, a thyroid function test, and ultrasonography are performed.

Results

A total of 198 pregnant women in their third trimester were recruited. Their mean age was 35.1±3.5 years, and 78 (39.4%) of them were pregnant with twins. Thirty-three (16.7%) of them had a previous history of thyroid disease.

Conclusion

Korea is an iodine-replete area. In particular, lactating women in Korea are commonly exposed to excess iodine due to the traditional practice of consuming brown seaweed soup postpartum. The study of the IBM cohort is expected to contribute to developing guidelines for optimal iodine nutrition in pregnant or lactating women.

Citations

Citations to this article as recorded by

Investigating Birth and Thyroid Outcomes of Maternal-Fetal Environmental Exposures (IBM-E): A Cohort Protocol for Dietary Iodine and Endocrine Disruptors
Yun Ji Jung, Jeong Eun Shin, Ju-hee Yoon, Suhra Kim, Hayan Kwon, Sungbo Shim, Dong Yeob Shin, Minseo Gim, Younglim Kho, JoonHo Lee
Endocrinology and Metabolism.2025; 40(6): 940. CrossRef
Exposure to and Transplacental Transfer of Per- and Polyfluoroalkyl Substances in a Twin Pregnancy Cohort in Korea
Na-Youn Park, Sun Wook Cho, Ye Eun Seo, Heeyeon Chae, Inae Lee, Young Ah Lee, Jong Kwan Jun, Eun Na Kim, Jeong-Won Oh, Kyungho Choi, Younglim Kho
Environmental Science & Technology.2024; 58(48): 21120. CrossRef
High intakes of iodine among women during pregnancy and the postpartum period has no adverse effect on thyroid function
Dal Lae Ju, Sun Wook Cho, Chae Won Chung, Young Ah Lee, Gi Jeong Cheon, Young Joo Park, Choong Ho Shin, Jong Kwan Jun, June-Key Chung, Sue K. Park, YoonJu Song
European Journal of Nutrition.2023; 62(1): 239. CrossRef
Associations between maternal thyroid function in pregnancy and child neurodevelopmental outcomes at 20 months in the Seychelles Child Development Study, Nutrition Cohort 2 (SCDS NC2)
Anna M. Monaghan, Maria S. Mulhern, Emeir M. Mc Sorley, J.J. Strain, Theresa Winter, Edwin van Wijngaarden, Gary J. Myers, Philip W. Davidson, Conrad Shamlaye, Jude Gedeon, Alison J. Yeates
Journal of Nutritional Science.2021;[Epub] CrossRef

Poorly Differentiated Thyroid Carcinoma: 10-Year Experience in a Southeast Asian Population: Marc Gregory Yu, Jonathan Rivera, Cecilia Jimeno; Endocrinol Metab. 2017;32(2):288-295. Published online June 23, 2017; DOI: https://doi.org/10.3803/EnM.2017.32.2.288

7,823 View
70 Download
23 Web of Science
18 Crossref

Abstract PDF PubReader

Background

No previous studies have been published on poorly differentiated thyroid carcinoma (PDTC) in Southeast Asia.

Methods

We included all adult PDTC patients diagnosed using the Turin criteria at the Philippine General Hospital from 2006 to 2015. The data collected included demographics, clinical presentation, histopathology, treatment, and outcomes. Tests of association were employed to compare these data with foreign studies on PDTC, as well as with local studies on well differentiated thyroid carcinoma (WDTC) and anaplastic thyroid carcinoma (ATC).

Results

Eighteen PDTC cases were identified. The median age was 62 years old, with the majority being females. All patients had goiter on presentation, and most were stage IV at the time of diagnosis. In terms of PDTC subtype, insular and trabecular patterns were equally common. Extrathyroidal extension was documented in eight patients, while five patients each had nodal and distant metastasis. All but one patient underwent surgery; however, less than half received adjuvant radioiodine therapy. The 5-year survival rate was 83%. Three patients (16.7%) died at a median of 12 months after diagnosis. Nine (50%) are still alive with persistent and/or recurrent disease at a median of 39 months after diagnosis.

Conclusion

The behavior of PDTC in this Southeast Asian population was found to be similar to patterns observed in other regions, and exhibited intermediate features between WDTC and ATC. Appropriate surgery provided excellent 5-year survival rates, but the role of adjuvant therapy remains unclear. Larger studies are needed to identify prognostic factors in this population.

Citations

Citations to this article as recorded by

siRNA-based Therapeutics in Hormone-driven Cancers: Advancements and benefits over conventional treatments
Sayani Saha, Reetika Tandon, Jhansi Sanku, Anchala Kumari, Rahul Shukla, Nidhi Srivastava
International Journal of Pharmaceutics.2025; 674: 125463. CrossRef
The 2024 revised clinical guidelines on the management of thyroid tumors by the Japan Association of Endocrine Surgery
Iwao Sugitani, Naomi Kiyota, Yasuhiro Ito, Naoyoshi Onoda, Tomo Hiromasa, Kiyomi Horiuchi, Seigo Kinuya, Tetsuo Kondo, Sueyoshi Moritani, Kiminori Sugino, Hisato Hara
Endocrine Journal.2025; 72(5): 545. CrossRef
Epidemiology, Diagnosis, and Management of Thyroid Cancer in the Philippines
Karol Ann T. Baldo, Ruby Anne N. King, Florence Giannina F. San Juan, Cecile C. Dungog, Jea Giezl N. Solidum, Jeremy A. Ceriales, Ma. Carmela P. dela Cruz, Frances Dominique V. Ho, Nicole Picart, Aldrin Nico R. Plantado, Jessica Perez, Jervy P. Garcia, Jo
Indian Journal of Surgical Oncology.2025;[Epub] CrossRef
Aggressive Thyroid Carcinomas Clinical and Molecular Features: A Systematic Review
Sorina Schipor, Mihai Alin Publik, Dana Manda, Mihail Ceausu
International Journal of Molecular Sciences.2025; 26(12): 5535. CrossRef
2025 American Thyroid Association Management Guidelines for Adult Patients with Differentiated Thyroid Cancer
Matthew D. Ringel, Julie Ann Sosa, Zubair Baloch, Lindsay Bischoff, Gary Bloom, Gregory A. Brent, Pamela L. Brock, Roger Chou, Robert R. Flavell, Whitney Goldner, Elizabeth G. Grubbs, Megan Haymart, Steven M. Larson, Angela M. Leung, Joseph Osborne, John
Thyroid®.2025; 35(8): 841. CrossRef
Prognosis of Poorly Differentiated Thyroid Carcinoma: A Systematic Review and Meta-Analysis
Ji Young Kim, Jae Kyung Myung, Soyun Kim, Kyung Tae, Yun Young Choi, Soo Jin Lee
Endocrinology and Metabolism.2024; 39(4): 590. CrossRef
Poorly differentiated thyroid carcinomas: conceptual controversy and clinical impact
Andrés Coca-Pelaz, Juan P. Rodrigo, Abbas Agaimy, Michelle D. Williams, Nabil F. Saba, Sandra Nuyts, Gregory W. Randolph, Fernando López, Vincent Vander Poorten, Luiz P. Kowalski, Francisco J. Civantos, Mark E. Zafereo, Antti A. Mäkitie, Oded Cohen, Iain
Virchows Archiv.2024; 484(5): 733. CrossRef
Management of Poorly Differentiated Thyroid Cancer and Differentiated High-Grade Thyroid Carcinoma
Iram S. Alam, Kepal N. Patel
Surgical Clinics of North America.2024; 104(4): 751. CrossRef
Poorly differentiated thyroid carcinoma: molecular, clinico-pathological hallmarks and therapeutic perspectives
Valentina CIRELLO, Carla GAMBALE, Alyaksandr V. NIKITSKI, Chie MASAKI, João ROQUE, Carla COLOMBO
Panminerva Medica.2024;[Epub] CrossRef
The Long Journey towards Personalized Targeted Therapy in Poorly Differentiated Thyroid Carcinoma (PDTC): A Case Report and Systematic Review
Odysseas Violetis, Panagiota Konstantakou, Ariadni Spyroglou, Antonios Xydakis, Panagiotis B. Kekis, Sofia Tseleni, Denise Kolomodi, Manousos Konstadoulakis, George Mastorakos, Maria Theochari, Javier Aller, Krystallenia I. Alexandraki
Journal of Personalized Medicine.2024; 14(6): 654. CrossRef
I-131 Avid Tumor Thrombus in a Case of Poorly Differentiated Thyroid Cancer
Sana Munir Gill, Aamna Hassan, Humayun Bashir, Waqas Shafiq
Molecular Imaging and Radionuclide Therapy.2023; 32(2): 178. CrossRef
Prognostic Impact of Focal Poorly Differentiated Areas in Follicular Differentiated Thyroid Cancer: Is It a Distinct Entity from Poorly Differentiated Thyroid Cancer?
Ramakanth Bhargav Panchangam, Pradeep Puthenveetil, Sabaretnam Mayilvaganan
Indian Journal of Surgical Oncology.2022; 13(1): 157. CrossRef
Newly proposed survival staging system for poorly differentiated thyroid cancer: a SEER-based study
W. Sun, Z. Wang, J. Xiang, Y. Qin, F. Zhang, H. Zhang
Journal of Endocrinological Investigation.2022; 46(5): 947. CrossRef
Clinicopathological Characteristics and Prognosis of Poorly Differentiated Thyroid Carcinoma Diagnosed According to the Turin Criteria
Jiapeng Huang, Wei Sun, Qingfu Zhang, Zhihong Wang, Wenwu Dong, Dalin Zhang, Chengzhou Lv, Liang Shao, Ping Zhang, Hao Zhang
Endocrine Practice.2021; 27(5): 401. CrossRef
Osteopontin Expression in Thyroid Cancer: Deciphering EMT-Related Molecular Mechanisms
Bruna Prunes Pena Baroni Viana, Amanda Vitória Pampolha Gomes, Etel Rodrigues Pereira Gimba, Luciana Bueno Ferreira
Biomedicines.2021; 9(10): 1372. CrossRef
Poorly differentiated thyroid carcinoma (PDTC) characteristics and the efficacy of radioactive iodine (RAI) therapy as an adjuvant treatment in a tertiary cancer care center
Shivakumar Thiagarajan, Aamir Yousuf, Ratan Shetty, Harsh Dhar, Yash Mathur, Deepa Nair, Sandeep Basu, Asawari Patil, Shubadha Kane, Sarbani Ghosh-Laskar, Devendra Chaukar
European Archives of Oto-Rhino-Laryngology.2020; 277(6): 1807. CrossRef
Major vessel invasion by thyroid cancer: a comprehensive review
Michael S. Xu, Jennifer Li, Sam M. Wiseman
Expert Review of Anticancer Therapy.2019; 19(2): 191. CrossRef
Poorly differentiated thyroid carcinoma and poorly differentiated area in differentiated thyroid carcinoma: is there any difference?
Raouef Ahmed Bichoo, Anjali Mishra, Niraj Kumari, Narendra Krishnani, Gyan Chand, Gaurav Agarwal, Amit Agarwal, Saroj Kanta Mishra
Langenbeck's Archives of Surgery.2019; 404(1): 45. CrossRef

Review Article

Update on Familial Hypercholesterolemia: Diagnosis, Cardiovascular Risk, and Novel Therapeutics: Sang-Hak Lee; Endocrinol Metab. 2017;32(1):36-40. Published online January 19, 2017; DOI: https://doi.org/10.3803/EnM.2017.32.1.36

7,509 View
65 Download
13 Web of Science
12 Crossref

Abstract PDF PubReader

In recent studies, the reported prevalence of heterozygous familial hypercholesterolemia (FH) has been higher than in previous reports. Although cascade genetic screening is a good option for efficient identification of affected patients, diagnosis using only clinical criteria is more common in real clinical practice. Cardiovascular risk is much higher in FH patients due to longstanding low density lipoprotein cholesterol (LDL-C) burden and is also influenced by other risk factors. Although guidelines emphasize aggressive LDL-C reduction, the majority of patients cannot reach the LDL-C goal by conventional pharmacotherapy. Novel therapeutics such as proprotein convertase subtilisin/kexin type 9 inhibitors have shown strong lipid lowering efficacy and are expected to improve treatment results in FH patients.

Citations

Citations to this article as recorded by

Pathogenic LDLR Variants (c.103 C>T and c.2416dup) in ligand-binding and cytosolic domains in Saudi familial hypercholesterolemia: Molecular characterization and computational insights
Hadiah Bassam Al Mahdi, Noor Ahmad Shaik, Babajan Banaganapalli, Sherif Edris, Rawabi Zahed, Hanan Abdelhalim ElSokary, Hussam Daghistani, Yousef Almoghrabi, Safa Bayashut, Alaa Y. Edrees, Abdulrahman Mujalli, Eman Alefishat, Ramu Elango, Zuhier Awan
Computational and Structural Biotechnology Journal.2025; 27: 3770. CrossRef
Medicine‐Food Plant Polysaccharides Modulate Diabetes and Diabetic Complications Through Maintaining Gut Function: A Review
Yi Long, Wanglong Yu, Pingping Yang, Minxuan Xu, Jitao Ling, Yuting Wu, Xiao Liu, Liu Ouyang, Yan Xiong, Jianping Liu, Yiming Gan, Jing Zhang, Peng Yu, Deju Zhang
Food Frontiers.2025; 6(6): 2720. CrossRef
Effectiveness and Safety of a Fixed-Dose Combination of Valsartan and Rosuvastatin (Rovatitan® Tablet) in Patients with Concomitant Hypertension and Hyperlipidemia: An Observational Study
Kwang Je Lee, Jae-Kean Ryu, Yun-Hyeong Cho, Won Yong Shin, Jeong Su Kim, Young Won Yoon, Ji Yong Jang, Won Ho Kim, Jong Wook Beom, Seok-Min Kang
Drug Design, Development and Therapy.2023; Volume 17: 1047. CrossRef
Role of PCSK9 Inhibitors in Patients with Familial Hypercholesterolemia
Brian Tomlinson, Nivritti Gajanan Patil, Manson Fok, Christopher Wai Kei Lam
Endocrinology and Metabolism.2021; 36(2): 279. CrossRef
Identification and Functional Characterization of a Low-Density Lipoprotein Receptor Gene Pathogenic Variant in Familial Hypercholesterolemia
Hong-Yan Shu, Wei Zhang, Cong-Cong Zheng, Man-Yun Gao, Yong-Cun Li, Yan-Gang Wang
Frontiers in Genetics.2021;[Epub] CrossRef
Gut Microbiota and Complications of Type-2 Diabetes
Camelia Oana Iatcu, Aimee Steen, Mihai Covasa
Nutrients.2021; 14(1): 166. CrossRef
LDLR Gene Mutation p.Asp360His and Familial Hypercholesterolemia in a Mexican Community
Teresita De Jesús Hernández Flores, Juan Ramón González García, Yoaly Josefina Sánchez López, Norma Alejandra Vázquez Cárdenas, Ana Gabriela Colima Fausto, Sergio Yair Rodríguez Preciado, María Teresa Magaña Torres
Archives of Medical Research.2020; 51(2): 153. CrossRef
A Rare Double Heterozygous Mutation in Low-Density Lipoprotein Receptor and Apolipoprotein B-100 Genes in a Severely Affected Familial Hypercholesterolaemia Patient
Lilla Juhász, István Balogh, László Madar, Beáta Kovács, Mariann Harangi
Cureus.2020;[Epub] CrossRef
Efficacy and Safety of a Fixed-Dose Combination of Candesartan and Rosuvastatin on Blood Pressure and Cholesterol in Patients With Hypertension and Hypercholesterolemia: A Multicenter, Randomized, Double-Blind, Parallel Phase III Clinical Study
Kyoung Im Cho, Bo Hyun Kim, Yong Hyun Park, Jeong-Cheon Ahn, Sang Hyun Kim, Wook Jin Chung, Weon Kim, Il Suk Sohn, Jin Ho Shin, Yong Jin Kim, Kiyuk Chang, Cheol Woong Yu, Soe Hee Ahn, Seok Yeon Kim, Jae Kean Ryu, Jong Young Lee, Bum Kee Hong, Taek Jong Ho
Clinical Therapeutics.2019; 41(8): 1508. CrossRef
Diagnosis and Treatment of Heterozygous Familial Hypercholesterolemia
Mary P. McGowan, Seyed Hamed Hosseini Dehkordi, Patrick M. Moriarty, P. Barton Duell
Journal of the American Heart Association.2019;[Epub] CrossRef
Autosomal recessive hypercholesterolemia: Case report
Zaneta Petrulioniene, Urte Gargalskaite, Violeta Mikstiene, Rimvydas Norvilas, Egle Skiauteryte, Algirdas Utkus
Journal of Clinical Lipidology.2019; 13(6): 887. CrossRef
Q192R polymorphism in the PON1 gene and familial hypercholesterolemia in a Saudi population
Khalid Khalaf Alharbi, May Salem Alnbaheen, Fawiziah Khalaf Alharbi, Rana M. Hasanato, Imran Ali Khan
Annals of Saudi Medicine.2017; 37(6): 425. CrossRef

Case Reports

A Case of Primary Adrenal Insufficiency in a Patient with Acquired Immunodeficiency Syndrome.: Jae Ho Choi, Suk Chon, Yu Chul Hwang, Jun Seong Son, Seung Joon Oh, Kyu Jeung Ahn, Ho Yeon Chung, Jeong Taek Woo, Sung Woon Kim, Jin Woo Kim, Young Seol Kim, In Kyung Jeong; Endocrinol Metab. 2011;26(3):253-257. Published online September 1, 2011; DOI: https://doi.org/10.3803/EnM.2011.26.3.253

3,422 View
36 Download
1 Crossref

Abstract PDF

The adrenal gland is the most commonly involved endocrine organ in patients infected with the human immunodeficiency virus (HIV). Adrenal function abnormality is more common in HIV patients than in the general population. It is important to recognize the condition of adrenal insufficiency, as this adrenal disorder may prove fatal if left untreated. Herein, we report a case of primary adrenal insufficiency in a 37-year-old male patient with acquired immunodeficiency syndrome. The patient complained of fever, general weakness, and fatigue. Impaired adrenal function was noted in the rapid ACTH stimulation test. After steroid supplementation, the patient's symptoms were improved. Therefore, HIV care physicians should ascertain adrenal dysfunction in HIV patients when they complain of fever and general weakness.

Citations

Citations to this article as recorded by

A Case Report of Adrenal Insufficiency Treated with Korean Medicine
Young-ji Kim, Jung-yeon Kwon, Ho-yeon Go, Kyung-hwan Kong
The Journal of Internal Korean Medicine.2017; 38(5): 583. CrossRef

A Case of Methimazole-induced Pancytopenia: Successful Treatment with Recombinant Human Granulocyte Colony-stimulating Factor.: Joo Hyoung Lee, Jihyun Lee, Sang Hun Sung, Sung Hwa Bae, Sang Gyung Kim, Hoon Kyu Oh; J Korean Endocr Soc. 2006;21(6):548-551. Published online December 1, 2006; DOI: https://doi.org/10.3803/jkes.2006.21.6.548

3,141 View
30 Download
1 Crossref

Abstract PDF

Methimazole has remained the cornerstone for the treatment of hyperthyroidism since 1940's and it is a well-tolerated antithyroid drug. Pancytopenia is one of the major side effects of methimazole, but its occurrence is very rare. There have been some case reports about methimazole-induced pancytopenia that was treated with recombinant human granulocyte colony-stimulating factor (G-CSF), but its usefulness is still controversial. We present here a case of a 50-year-old female who had been treated with methimazole for hyperthyroidism and she subsequently presented pancytopenia. G-CSF was given for 10 days and she successfully recovered from the pancytopenia.

Citations

Citations to this article as recorded by

A Case of Graves' Disease with Pancytopenia
Jong Ho Shin, Hyun Jin Kim, Si Bum Kim, Dong Pil Kim, Bong Suk Ko, Dong Soon Kim, Ji Myung Kim, Soo Jung Gong, Jung-Ae Lee
Journal of Korean Endocrine Society.2009; 24(4): 272. CrossRef

Original Articles

A Retrospective Review of the Effectiveness of Recombinant Human TSH-Aided Radioiodine Treatment of Differentiated Thyroid Carcinoma.: Min Ah Na, Sun Hae Shin, Yang Ho Kang, Seok Man Son, In Joo Kim, Yong Ki Kim; J Korean Endocr Soc. 2006;21(4):274-280. Published online August 1, 2006; DOI: https://doi.org/10.3803/jkes.2006.21.4.274

2,652 View
19 Download

Abstract PDF: BACKGROUND
The aim of the study was to evaluate the biochemical effects of recombinant human thyroid stimulating hormone (rhTSH) as an adjunct to radioiodine (RI) treatment of a differentiated thyroid carcinoma (DTC). We retrospectively reviewed the clinical response rates of DTC patients treated with RI after thyroid hormone withdrawal and compared with those after rhTSH stimulation. METHOD: We included the patients treated with RI for locally recurrent DTC from February 1, 2002 to August 31, 2005 and followed with diagnostic studies at our hospital. Forty totally (or near totally) thyroidectomized adults were included in this study. Nine patients underwent RI treatment after rhTSH stimulation while euthyoid on L-thyroxine (LT4), and 31 patients were treated with RI after thyroid hormone withdrawal. The clinical response was defined as >25% decrease in serum thyroglobulin (Tg) level on LT4 3 months after the RI treatment. RESULTS: In each group, serum Tg levels were significantly decreased 3 months after the RI treatment. And we found that 77.8 and 71.0% of those prepared by rhTSH and LT4 withdrawal, respectively, had clinical responses 3 months after the RI treatment by our criteria and there was no significant difference in response rates between two groups (P=0.238). CONCLUSIONS: Given the biases that exist in retrospective studies, at the current time we cannot recommend the routine use of rhTSH to prepare RI treatment of DTC. However, our study provided preliminary evidence that rhTSH effectively aided RI treatment of DTC at least to an equivalent degree as LT4 withdrawal.

Standardization of Isolation Procedure and Analysis of Variables on Successful Isolation of Islet from the Human Pancreas.: Song Cheol Kim, Duck Jong Han, Ik Hee Kim, Yoo Me We, Yang Hee Kim, Jin Hee Kim, Ji He Back, Dong Gyun Lim; J Korean Endocr Soc. 2006;21(1):22-31. Published online February 1, 2006; DOI: https://doi.org/10.3803/jkes.2006.21.1.22

2,402 View
21 Download

Abstract PDF: BACKGROUND
Identifying the donor and isolation-related factors during the islet isolation would be greatly helpful to improve the result of human islet isolation for successful clinical islet transplantation. METHODS: Sixty-nine pancreata from cadaveric donors were isolated with standard protocol and analyzed to identify the donor factors and isolation variables for successful isolation. Islet isolations recovered > or = 100,000 Islet Equivalent (IEQ, n=53) were compared to islet mass less than 100,000 IEQ (n=16). RESULTS: The mean islet recovery was 216.0 x 10(3) +/- 173.7 x 10(3) (IEQ) before purification and 130.6 x 10(3) +/- 140.2 x 10(3) (IEQ) after purification. Mean purity was 54 +/- 31%. Mean age of donor was 31.2 +/- 13.2 year and mean cold ischemic time was 6.9 +/- 6.2 hour. Quality of isolated islets was acceptable in terms of bacterial culture, viability and secretory function in vitro and in vivo. In univariate analysis on successful isolation, status of pancreas was the only significant factor and sex, duration of collagenase expansion and digestion time were marginal factors. Stepwise multivariate logistic regression analysis showed donor sex, status of pancreas and digestion time were significant factors for the successful islet isolation. CONCLUSION: This study confirms some donor factors and variables in isolation process can influence the ability to obtain the successful isolation of human islet. Enough experiences and pertinent review of donor and isolation factors can make islet isolation successful, supporting the clinical islet transplantation without spending of cost.

Case Report

A Case of Severe Thyrotoxicosis Induced by Hydatidiform Mole.: Jae Hak Lee, Jong Kun Park, Soon Hyo Kwon, Ji Oh Mok, Ji Sung Yoon, Yeo Joo Kim, Hyung Kyu Park, Chul Hee Kim, Sang Jin Kim, Hae Hyeog Lee, Gye Hyun Nam, Gye Hyun Kwan, Eun Suk Ko, Dong Won Byun, Kyo Il Suh, Myung Hi Yoo; J Korean Endocr Soc. 2003;18(4):420-425. Published online August 1, 2003

1,784 View
29 Download

Abstract PDF: Human chorionic gonadotropin (HCG) is one of the glycoproteins families synthesized by the placenta, and consists of 2 noncovalently joined subunits, namely, alpha and beta. The alpha and beta-subunits have a structural homology with the alpha and beta-subunits of TSH and LH. The thyrotropic action of HCG results from its structural similarity to TSH, so beta-HCG can bind to the TSH receptor in the thyroid gland. A high level of HCG, accompanied by an increased thyroid hormone level, can be observed in gestational trophoblastic diseases (GTD), such as a hydatidiform mole or a choriocarcinoma. However, the clinical symptoms of hyperthyroidism in GTD are rarely observed. A 27-years-old woman, admitted due to an amenorrhea of 11 weeks duration, with thyrotoxic symptoms, such as weight loss, palpitation, sweating, tremor, heat intolerance and anxiety, was evaluated. Her serum free T4 level was 8 times higher than normal, and her serum beta-HCG level was over 1,000,000IU/L. She had a curettage operation, with the pathological findings of a complete hydatidiform mole. These thyrotoxic symptoms developed due to a hydatidiform mole, and were accompanied with a highly increased serum beta-HCG level. After evacuation of the molar tissue, the thyroid hormone and thyrotoxic symptoms normalized. Here, this case is reported, with brief review of the literature.

Randomized Controlled Trial

Effect of Dexamethasone and 1,25(OH)2D3 on Proliferation and Osteogenic Differentiation of Cultured Human Bone Marrow Stromal Cells.: Hye Soo Kim, Il Woo Lee, Jong Min Lee, Chang Hwan Han, Jin Hyung Sung, Min Young Park, Gil Son Khang, Hai Bang Lee; J Korean Endocr Soc. 2002;17(2):206-217. Published online April 1, 2002

1,707 View
19 Download

Abstract PDF: BACKGROUND
It is crucial, in the case of regenerating bone by tissue-engineering technique, that osteoblast progenitors are proliferated and induced to differentiate to osteoblasts sequentially at the proper time. Osteoblasts can be obtained from bone itself or from osteoblast progenitors in bone marrow, even though the amount of human marrow stromal cells in marrow aspirate is usually scanty. These cells, however, have been known demonstrate the potential to easily proliferate and differentiate in osteoblasts, chondroblasts or adipocytes according to different microenvironmental factors. We evaluated the effect of dexamethasone and 1,25(OH)2D3 on the proliferation, differentiation, and mineralization of human marrow stromal cells in vitro. METHODS: We used twelve bone marrow aspirates obtained from different healthy bone marrow donors. Culture plates were randomly divided into the following four experimental groups; group 1 was cultured with control medium only, group 2 with control medium containing 1,25(OH)2D3, group 3 with control medium containing dexamethasone, and group 4 with control medium containing both 1,25(OH)2D3 and dexamethasone. 3H-thymidine uptake, protein content of cell lysates, alkaline phosphatase activities and alkaline phosphatase histochemistries were measured. Alizarin Red-S staining and quantification of dissolved dye were also performed. RESULTS: Combined stimulation of marrow stromal cells with both 1,25(OH)2D3 and dexamethasone was found to be effective to maintain stable long-term culture of the cells and to increased differentiation and mineralization of the cells. Synthesis and mineralization of matrix were highest when the cells were stimulated with 1,25(OH)2D3 alone during the early culture phase. However, 1,25(OH)2D3 shortened the lifespan of the cells. Interestingly, mineralization was higher in female donor cells than in male donor cells when stimulated with dexamethasone alone or with both dexamethasone and 1,25(OH)2D3. Neither 1,25(OH)2D3 nor dexamethasone affected cell proliferation. CONCLUSION: Our results suggest that the synergistic effect of dexamethasone and 1,25(OH)2D3 is important in maintaining long-term culture and differentiation of human marrow stromal cells. It is preferable to administer 1,25(OH)2D3 after the attachment of cultured osteoblasts to biomaterials has been established, since it could shorten cell survival despite the great increase of mineralization at the early culture phase.

Original Articles

Effect of weight loss on cerebrospinal Fluid and Plasma Concentrations of NPY, alpha -MSH and leptin in Obese Women.: Su Youn Nam, Kyung Wook Kim, Jun Hee Lee, Soo Jee Lee, Kyung Rae Kim, Young Duck Song, Sung Kil Lim, Hyun Chul Lee, Kap Bum Huh; J Korean Endocr Soc. 2001;16(2):199-209. Published online April 1, 2001

1,503 View
17 Download

Abstract PDF: BACKGROUND
Although leptin and its principal mediators, neuropeptide Y (NPY) and -melanocyte stimulating hormone (MSH) are postulated to play a pivotal role in the energy balance in experimental animals, the physiologic roles of leptin and its molecular targets are not fully identified in cases of human obesity. METHODS: The subjects consisted of 16 obese women (mean BMI 35.6 kg/m2) before and after weight loss that was induced by a 2 week-very low caloric diet (800 kcal/day) and 14 normal weight women (who had a mean BMI of 20.4 kg/m2). We evaluated the plasma and cerebrospinal fluid (CSF) leptin, NPY and alpha -MSH levels and their relationship in normal weight and obese women. Additionally, changes of these peptides during a negative energy balance (800 kcal/day) were assessed in causes of human obesity. RESULTS: Obese subjects exhibited a 6.3-fold higher plasma leptin level (21.9+/-1.2 vs 3.5+/-0.4 ng/mL, p<0.05) and a 2.8-fold higher CSF leptin level (0.29+/-0.02 vs 0.10+/-0.01 ng/mL, p<0.05) compared to control subjects. The CSF/plasma leptin ratio in normal weight subjects was 2.3-fold higher than that in obese subjects. After a weight loss in obese subjects, the plasma leptin level decreased by 40% and the CSF level decreased by 51%. The CSF/plasma leptin ratio was slightly lower than the baseline level. There was a positive linear correlation between CSF and plasma leptin level at the baseline in obese subjects (r= 0.74, p<0.05) and a positive logarithmic correlation in normal weight subjects and in obese subjects after a weight loss (r= 0.66, p<0.05). The BMI negatively correlated with the CSF/plasma leptin ratio (r=-0.86, p<0.05) in any subjects. Neither the baseline plasma levels nor the baseline CSF levels of NPY were different between the normal weight subjects and obese subjects. After a weight loss the CSF NPY level decreased significantly compared to the baseline values in obese subjects. The alpha -MSH levels in plasma and CSF did not differ significantly from controls in obese subjects at the baseline or after a weight loss. The baseline CSF leptin level neither correlated with the baseline CSF NPY level nor the baseline CSF alpha -MSH level. CONCLUSION: These results demonstrated that the efficiency of leptin delivery to the CNS is reduced in human obesity and that the CNS leptin uptake involves the combination of saturable and unsaturable mechanisms. A marked reduction in the CSF leptin levels compared to the plasma level after a weight loss in obese subjects can be a potent stimulus for the body to regain weight. In contrast to the results that were observed in experimental animals, the CSF NPY and alpha -MSH did not differ from the controls in human obesity and there was no significant correlation between the CSF leptin and CSF of these neuropeptides. This could have resulted from leptin resistance in cases of human obesity although the mechanisms for this resistance remain to be determined.

Expression of Human Sodium Iodide Symporter mRNA in Papillary Thyroid Carcinoma.: Hong Kyu Kim, Il Min Ahn, Young Il Kim, Eun Sook Kim, Hyun Soo Park, Ki Young Park, Seok Jun Hong; J Korean Endocr Soc. 1998;13(2):181-188. Published online January 1, 2001

1,582 View
17 Download

Abstract PDF: BACKGROUND
The sodium iodide symporter(NIS) is a plasma membrane protein which is respoasibIe for iodide transport into thyroid cell. The cDNA sequence of NIS has recently been cloned from rat and human. Intrinsic ability and its differences in iodide accumulation have been exploited as a useful tool for diagnosis and therapy of thyroid diseases. It is also known that some differentiated thyroid cancers do not take up radioactive iodine at therapeutic dose. METHODS: To understand the expression and regulation of NIS in thyroid tumars, we measured the expressons of human NIS(hNIS), TSH-receptor(R), and thyroglohulin(Tg) mRNAs from papillary thyroid carcinoma(PTC) tissues by reverse transcriptase-polymerase chain reaction (RT-PCR) and RNase protection assay(RPA). RESULT: By RT-PCR analysis, 87% of PTC expressed hNIS mRNA, but the degree of expression were variable. Interestingly, 32% of PTC showed significant level of hNIS expression even though pre-operative technetium thyroid scan of all thyroid tumors were cold but the level was lower than normal control tissues. All of PTC showed the expressions of Tg and TSH-R mRNAs and there was a correlation between hNIS mRNA and TSH-R mRNA(Rsq 0.35, p=0.01). By RPA, the expression of hNIS and TSH-R in normal control tissue were detected with 20microgram and 40microgram of total RNA respectively, but the higher concentrations(> or =60microgram for hNIS and > or =40microgram for TSH-R) were required to detect in PTC, showing that tbe expression of hNIS in FTC was lower than TSH-R expression. CONCLUSION: PTC tends to lose hNIS mRNA expression earlier than TSH-R mRNA and the measurement of hNIS mRNA in PTC may be useful as an indicator of the therapeutic response to radioactive iodine.

Measurements of Thyroid Stimulation Blocking Antibody Activities by Chinese Hamster Ovary ( CHO ) cells Expressing Human TSH Receptors in Patients with Primary Hypothyroidism.: Won Bae Kim, Bo Youn Cho, Do Joon Park; J Korean Endocr Soc. 1997;12(1):18-32. Published online January 1, 2001

1,481 View
18 Download

Abstract PDF: BACKGROUND
The Chinese hamster ovary cells transfected with human TSH receptor cDNA (hTSHR-CHO), expressing functional human TSH receptors, are known to be more sensitive in detection of thyroid stimulating antibodies than FRTL-5 cells. There has been no report on the usefulness of these cells to measure thyroid stimulation blocking antibody (TSBAb) activity which is frequently found in patients with primary myxedema, METHODS: We established the optimal assay condition of measurement of TSBAb using hTSHR-CHO cells, and simultaneously measured TSBAb activities with FRTL-5 cells and with hTSHR-CHO cells in 49 patients with primary myxedema, compared them with their thyrotropin binding inhibitor immunoglobulin (TBII) activities. RESULTS: 1) hTSHR-CHO cells specifically bound bTSH and were stimulated by bTSH in terms of cyclic AMP generation in a dose dependent manner. 2) Myxedema IgG suppressed TSH-stimulated cAMP production of hTSHR-CHO cells in a dose dependent manner reaching plateau at the concentration of I g/L. Normal pooled IgG has no suppressive action at the concentration of less than 1 g/L, but caused significant suppression at the concentration of greater than 1g/L. 3) TSBAb activities measured by hTSHR-CHO cells in 49 patients with primary myxedema were as follows: Four of 25 TBII-negative cases (16%) and 22 of 24 TBII-positive cases (92%) had TSBAb activities. Most of TSBAb positive patients (95%), especially in TBII positive cases, showed very high activities of more than 90%. 4) TSBAb activities measured by hTSHR-CHO cells and those by FRTL-5 cells were both positive in 24 patients (49%), both negative in 18 patients (37%), and were discrepant in 7 patients (14%). The TSBAb activities measured with hTSHR-CHO cells and those measured with FRTL-5 cells were significantly correlated (r=0.71, p< 0.01). 5) Forty five percent of patients with primary myxedema had all of 3 kinds of activities (TBII, hTSHR-CHO cell TSBAb, FRTL-5 cell TSBAb), 37% of them had none of 3 activities and 18% of them had 1 or 2 kinds of activities only. CONCLUSION: The usefulness of hTSHR-CHO cells in measurements of TSBAb activities were confirmed. The TSBAb activities of most patients with primary myxedema measured by hTSHR-CHO cells were concordant with those measured by FRTL-5 cells. However, a small subset of patients (18%) had discrepant results in assays of TSH receptor antibodies according to the differences in TSH receptors (rat, human and porcine) used in assay. Such discrepancy may be explained by heterogeneity in epitopes for blocking TSH receptor antibodies.

Clinical Significance of Human Sodium Iodide Symporter mRNA Expressions in Primary and Metastatic Papillary Thyroid Carcinoma.: Seong Jin Lee, Hyun Joo Park, Eun Ju Lee, Ha Young Kim, Jin Kyu Koh, Ki Young Park, Sung Bae Kim, Gyung Yup Gong, Suk Joon Hong, Il Min Ahn, Sang Hee Kim; J Korean Endocr Soc. 1999;14(3):514-519. Published online January 1, 2001

1,543 View
18 Download

Abstract PDF: BACKGROUND
The iodide transport into thyroid cells is an essential step in the biosynthesis of thyroid hormones. The sodium iodide symporter (NIS) which is responsible for iodide transport was cloned recently and identified as a plasma membrane glycoprotein. Recent report suggested the absence of human NIS (hNIS) mRNA expression of papillary carcinoma in thyroid indicates absence of response on radioiodine therapy for distant metastasis. To understand the change of hNIS expression at the stage of metastasis in papillary thyroid carcinomas, we evaluated the expression levels of hNIS mRNA in primary and lymph node metastatic papillary carcinoma tissues. METHODS: Seven pairs of primary and lymph node metastatic tissues were included in this study. The level of hNIS mRNA in lymph node metastatic tissues and primary tissues were evaluated by reverse transcriptase-polymerase chain reaction (RT-PCR). The level of GAPDH mRNA was used as internal control. RESULTS: Two among 6 lymph node metastatic tissues did not show hNIS mRNA even with significant hNIS expressions in papillary carcinoma tissues in thyroid. The levels of hNIS expression of remaining 4 lymph node metastatic tissues were lower than those of corresponding primary tissues. Interestingly, one case showed no hNIS expression in primary tissue, but significant hNIS expression in lymph node metastatic tissue. There was no correlation in hNIS mRNA expression between primary and lymph node metastatic tissues. CONCLUSION: No correlation was found in hNIS mRNA expression between primary and lymph node metastatic tissues, suggesting the measurements of hNIS mRNA level in primary tissues may not predict therapeutic response to radioactive iodine.

Anabolic Effects of Recombinant Human Parathyroid Hormone (1-84) on Bone Histomorphometry in Overiectomized Rats.: Young Jun Won, Du Hong Park, Jae Hyun Nam, Jong In Yook, Jin Kim, Kyung Rae Kim, Hyun Chul Lee, Kap Bum Huh, Sung Kil Lim; J Korean Endocr Soc. 1999;14(1):81-90. Published online January 1, 2001

1,531 View
21 Download

Abstract PDF: To evaluate the anabolic effects of human recombinant parathyroid hormone [hrPTH(1-84)], we examined effect of low-dose and high-dose of [hrPTH(1-84)] and estradiol on bone histomorphometry in ovariectomized rats. Sixty Sprague-Dawley female rats aged 8~10 weeks were used. Eight weeks after ovariectomy, or sham operation, rats were given daily sc injection of hrPTH (1-84), 30 pg/kg (OVX+L group), 150 pg/kg (OVX+H group), 17-estradiol (30 pg/kg, OVX+E group) or vehicle (OVX+V group) for 4 weeks. After double tetracycline labeling, all rats were killed at day 84. We completed the histomorphometric analysis of distal femoral metaphyseal cancellous bone for trabecular bone volume (TBV), mean trabecular plate thickness (MTPT), mean trabecular plate density (MTPD), mean trabecular plate separation (MTPS), mean osteoid seam width (OSW) and appositional rate (AR). The histomorphometric parameters (TBV, MTPT, OSW and AR) of trabecular bone mass in (OVX+E) group were higher than those in (OVX+V) group. The TBV of trabecular bone in PTH treated groups were higher than that in sham operated, (OVX+V) and (OVX+E) group. The histomorphometric parameters (TBV, MTPD, OSW and AR) of trabecular bone mass in (OVX+H) group showed a tendency to be higher than those in (OVX+L) group, but statistically not significant. In conclusion, Low dose (30 mg/kg) hrPTH (1-84) also shows a sufficient anabolic effect on trabecular bone.

Clinical Effects of E. cole Derived Authentic REcombinant Human Growth Hormone(DA-3002) in Children with Growth Hormone Deficiency.: Se Won Yang, Byung Chul Lee, Chul Woo Ko, Duk Hee Kim, Han Wook Yoo, Woo Young Chung; J Korean Endocr Soc. 1998;13(4):526-535. Published online January 1, 2001

1,590 View
28 Download

Abstract PDF: BACKGROUND
Recently authentic human growth hormone(hGH) has produced in the E coli K-12, W3110 by recombinant DNA tecbnology in Korea In this paper, the clinical efficacy and immunogenicity of this GH was shdied in 38 children with growth hormone deficiency during therapy of 1 year. METHODS: The subjects of this study were aged 4.9-13.9 years, diagnosed by failure of plasma GH to respond to insulin-induced hypoglycemia, arginine and/or L-dopa loading and height below -2 standard deviation of mean for their chronological age. Each patient received GH 0.5-0.7IU/kg/week subcutaneously in 6-7 divided doses. During treatment, vital signs, height, body weight and bone age were checked every 3 months. Complete blood count, urinalysis, blood chemistry and thyroid hormone were checked before and every 6 months. The measurement of serum IGF-1 level and antibody against hGH were performed before and every 6 months during therapy of I year. RESULT: The height velocities significantly increased from 3.3 +/- 1.5cm/year to 10.1 +/- 2.5 and 9.0 +/- 1.8cm/year at 6 and 12 months of therapy, respectively. The height standard deviation score for chronological age were significantly improved from -2.141.50 to -1.74 +/- 1.43 and -1.54 +/- 1.38 at 6 and 12 months of therapy with increasing ratio of bone age to chronological age from 0.72 +/- 0.15 at pretreatment to 0.76 +/- 0.15 at 6 month, 0.79 +/- 0.16 at 12 month of therapy. The plasma IGF-1 level significantly increased during treatment. One of 36 patients(2.8%) showed positive antibody against hGH after 1 year of treatment. During therapy of 1 year, unwanted and remarkable clinical side effect were not observed in all subjects. CONCLUSION: These results indicate that this E. coli derived authentic recombinant growth hormone is very effective in stimulating linear growth in children with growth hormone deficiency.

First
Prev
Page of 1
Next
Last

Search